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ABSTRACT 
Impact of Neurodevelopmental Genes on the Trajectory of ADHD severity: A Pilot Study 
by 
 
Agnieszka Mlodnicka 
 
Advisor: Dr. Jeffrey Halperin 
 
 
Attention-deficit/Hyperactivity Disorder (ADHD) is a chronic neurodevelopmental disorder characterized 
by symptoms of inattention and hyperactivity, and is associated with delays in neural development.  To 
assess the association of genes involved in neurodevelopment with symptoms and trajectory of ADHD, 
saliva was collected and genotyped from 145 participants from a longitudinal study of preschoolers who 
were followed annually for 7 years.  We examined four single nucleotide polymorphisms (SNPs) in genes 
associated with neurodevelopment: neuregulin-1 (NRG-1; SNP rs3924999), neurotropin-3 (NT-3; SNP 
rs6489630), brain-derived neurotrophic factor (BDNF; rs6265), and regulator of G protein signaling 4 
(RGS4; rs951439).  Hierarchical linear modeling revealed that neuregulin-1 and neurotropin-3 were 
associated with symptoms of inattention and hyperactivity at age 3-4 and throughout early childhood; 
however, these genes did not impact the trajectory of the inattentive and hyperactive symptoms over 
development.  Early environmental factors such as maternal diabetes, maternal substance use (tobacco, 
alcohol, illicit drug) were also analyzed along with each of the genetic factors.  Maternal gestational 
diabetes and NRG-1 risk allele, maternal gestational diabetes and BDNF, alcohol and NRG-1, and illicit 
drug use and NT-3 were all associated with greater inattentive and hyperactive symptoms.  Although the 
sample size is small for a genetics study, these findings can inform future investigations in understanding 
the neurodevelopment and heritability of ADHD. 
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Attention-Deficit Hyperactivity Disorder (ADHD) is a neurodevelopmental disorder characterized 
by inattention and/or hyperactivity/impulsivity above and beyond expected developmental and 
situational levels (American Psychiatric Association [APA], 2013).  ADHD is among the most common 
diagnoses in childhood, affecting approximately 5% of school age children (APA, 2013).  Symptoms of 
ADHD emerge in early childhood and for some individuals continue through adolescence and adulthood.  
Epidemiological studies indicate a higher proportion of boys diagnosed with ADHD than girls (Lahey, 
Miller, Gordon, & Riley, 1999).  In clinical settings, boys are six to ten times more likely to be referred for 
clinical assessment (Willcutt & Pennington, 2000) and are three to four times more likely to meet 
diagnostic criteria for the disorder compared to girls (Cantwell, 1996).  Despite clear operational 
diagnostic criteria for ADHD, children with the disorder are highly heterogeneous with regard to core 
symptoms, comorbidity, associated features, and life-span trajectories, and this heterogeneity has 
contributed to hindering research and understanding the underlying pathophysiology of the disorder. 
ADHD is a heterogeneous condition 
 The ADHD diagnosis is divided into three presentations, predominantly inattentive, 
predominantly hyperactive/impulsive, and combined (APA, 2013).  To meet diagnostic criteria for the 
inattentive or hyperactive/impulsive presentation, children need to display at least six out of nine 
possible symptoms from each category, respectively.  To meet criteria for the combined presentation, 
children need at least six symptoms in both categories.  Symptoms also need to be present in multiple 
settings, most commonly at home and school, and result in functional impairment.  Notably, girls who 
are diagnosed with ADHD are more likely to exhibit inattentive symptoms while boys are more likely to 
exhibit symptoms of hyperactivity and impulsivity (Levy, Hay, Bennett, & McStephen, 2005; Biederman 
et al., 2002).  The varying presentations and possible variation in the number and types of symptoms 
results in a clinically heterogeneous presentation of the disorder across individuals.  
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While ADHD most commonly emerges during the preschool and early school-age years, the 
trajectory of the disorder and type of presentation over time is also highly variable.  Some individuals 
continue to meet criteria for the diagnosis through adolescence and adulthood, while other individuals 
show a remittance of the disorder (Campbell, 1995; Connor, 2002).  Approximately 30-50% of childhood 
cases of ADHD remit by adolescence (Halperin, Trampush, Miller, & Newcorn, 2008) while remittance 
increases to as high as 85% by the age of 25 years (Faraone, Biederman, & Mick, 2006).  Some data 
indicate an overall decline in symptoms of hyperactivity/impulsivity and inattention with age 
(Biederman, Mick, & Faraone, 2000), while other data suggest that symptoms of 
hyperactivity/impulsivity decrease over time while symptoms of inattention persist (DuPaul & Stoner, 
2004; Wolraich et al., 2005).  During preschool, children are more likely to be diagnosed with ADHD-
Hyperactive/Impulsive Type, and as they reach school-age they are more likely to be diagnosed with 
ADHD - Combined Type (Lahey, Pelham, Loney, Lee, & Willcutt, 2005).  Furthermore, children who meet 
criteria for ADHD – Combined Type are more likely to continue to meet criteria the disorder in later 
development compared to those that meet for Inattentive or Hyperactive/Impulsive Subtype (Hart, 
Lahey, Loeber, Applegate, & Frick, 1995).  The lack of stability of symptom presentation and varying 
developmental trajectories contribute to the heterogeneity of the disorder. 
In addition, children with ADHD are likely to display a wide range of comorbid psychiatric 
disorders.  Among children with ADHD, as many as 70 – 80% meet diagnostic criteria for least one other 
psychiatric disorder, with many meeting criteria for multiple disorders, including other 
externalizing/behavioral as well as mood and anxiety disorders (Biederman, Newcorn & Sprich, 1991).  
Although children with ADHD are likely to exhibit many psychiatric disorders, most comorbidity is with 
other behavioral disorders.  As many as half of children with ADHD meet criteria for Oppositional 
Defiant Disorder (ODD) or Conduct Disorder (CD) (Swanson et al., 2001), with boys being more likely to 
exhibit these comorbid externalizing behaviors (Abikoff et al., 2002; Gaub & Carlson, 1997).  Yet 
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internalizing mood and anxiety disorders are not uncommon, reaching a 25% prevalence rate, often in 
combination with comorbid externalizing disorders (Schatz & Rostain, 2006). 
In addition to psychiatric comorbidities, compared to their typically-developing peers, children 
with ADHD have difficulties with social adjustment and social functioning (DuPaul, McGoey, Eckert & 
VanBrakle, 2001; Pfiffner, Calzada, & McBurnett, 2000), elevated rates of language (Helland, Posserud, 
Helland, Heimann, & Lundervold, 2012) and motor impairments (Fliers et al., 2008; Buitelaar, 2008), and 
are more likely to underachieve academically (Marshall, Hynd, Handwerk & Hall, 1997).  A recent meta-
analysis of comorbid learning disability and ADHD revealed a mean comorbidity rate of 45.1%, which 
included writing disorders, reading and/or math disabilities (DuPaul, Gormley, & Laracy, 2013).  The 
extremely high rates of comorbid disorders and functional difficulties further contribute to the 
heterogeneous profile of symptoms and patterns of functioning among children with ADHD. 
Biological Factors and ADHD 
 Research attempting to elucidate the etiology of ADHD has focused largely on genetic and 
neurodevelopmental factors, although it is clear that environmental influences are also important.  
Family studies have shown that biologically related family members of hyperactive children were more 
likely to have hyperactivity than adoptive relatives (Morrison & Stewart, 1973), and rates of ADHD are 
higher among biological relatives of adopted ADHD children compared to adopted relatives (Sprich, 
Biederman, Crawford, Mundy & Faraone, 2000).  Family studies rely on concordance of disease 
presentation from parents to off-spring, and presence of disease among related siblings.  A compilation 
of twin studies from the United States and Europe indicated that the mean heritability estimate of ADHD 
was .76, identifying ADHD as among the most heritable psychiatric disorders (Faraone et al., 2005).  
Although family and twin studies have indicated high heritability, as discussed in detail below, molecular 
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genetics studies have had very limited success in identifying specific genes that contribute to the 
expression of the phenotype.  
From a neurodevelopmental perspective, ADHD is associated with abnormalities in brain 
anatomy, connectivity, and neurotransmitter function.  Neuroimaging studies have indicated that 
children with ADHD have a delay in cortical maturation in frontal, striatal, parietal and cerebellar 
regions, with the most prominent delays in the prefrontal cortices (Castellanos et al., 2002a; Shaw et al., 
2007).  Individuals with ADHD have deficits in cortical gray matter, and decreases in volumes and cortical 
thickness of many brain regions, such as the superior frontal and orbital frontal cortex, anterior 
cingulate and inferior frontal cortex (Amico, Stauber, Koutsouleris & Frodl, 2011).  Childhood ADHD and 
the persistence of ADHD in adulthood is associated with under activation of the lateral inferior fronto-
striatal and ventromedial frontostriatal networks involved in attention and motivation (Cubillo, Halari, 
Smith, Taylor & Rubia, 2012; Konrad et al., 2010). 
Based largely on the pharmacological effects of stimulant medications, it has been suggested 
that catecholaminergic neurotransmitters, namely dopamine (DA) and noradrenalin (NA), are involved 
in the etiology of ADHD (Noble, 2003).  DA and NA activity in the prefrontal cortex appears to modulate 
higher cognitive executive functions, such as working memory, which is the ability to transiently hold 
and manipulate information necessary for generating forthcoming action (Durstewitz & Seamans, 2002).  
As children with ADHD have often been shown to be deficient in these cognitive functions (Willcutt, 
Doyle, Nigg, Faraone & Pennington, 2005), brain architecture and connectivity in these regions have 
been posited to play a role in the etiology of ADHD. 
ADHD is associated with areas of neuropsychological impairment which have also been posited 
to be a contributing factor to the disorder’s etiology.  Individuals with ADHD show deficiencies in 
executive functioning (EF) including effortful attention (Douglas, 1983), inhibitory control (Barkley, 
Grodzinsky, & DuPaul, 1992; Nigg, 2001; Schachar & Logan, 1990; Sergeant & Scholten, 1985), working 
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memory (Karatekin & Asarnow, 1998; Mariani & Barkley, 1997; Tannock, 1998), planning or set shifting 
(Harrier & DeOrnellas, 2005; Nigg, Hinshaw Carte, & Treuting, 1998), and delay aversion (Sonuga-Barke, 
2003).  Poor inhibitory control, the ability to completely and suddenly stop an activity or planned course 
of action (Logan & Cowan, 1984), has been linked to difficulties in working memory, self-regulation, 
internalization of speech and behavioral analysis and synthesis (Barkley, 1997).  However, only about 
half of children with ADHD have EF deficits and any specific type of EF deficit (e.g., working memory, 
inhibitory control, etc.) is present in even a smaller proportion of diagnosed children (Nigg, Willcutt, 
Doyle & Sonuga-Barke, 2005).  Thus, differences in profiles of neuropsychological functioning are an 
additional source of heterogeneity in ADHD.  
Genetics of ADHD 
Despite compelling twin, adoption and family study evidence for the high heritability of ADHD, 
molecular studies have not been very successful in identifying specific genes that account for this 
heritability.  Although limited and inconsistent, significant results in candidate gene research have 
implicated several genes involved in neurophysiological processes which are associated with ADHD.  The 
following will be a brief review of findings. 
Dopamine System Genes 
DA is a neurotransmitter, which has been posited to be associated with the etiology of ADHD, 
along with an array of other psychiatric and neurological disorders (e.g., alcohol use, nicotine use, 
substance use, mood disorders, posttraumatic stress disorder, schizophrenia, bipolar disorder, 
movement disorders, migraines) (Noble, 2003).  Interest in DA’s purported role in the pathophysiology 
of ADHD initially emerged from the mechanism of action of pharmacological treatment of ADHD.  First-
line treatment for ADHD often involves psychostimulants, such as methyphenidate and ampthetamine, 
which have been found to be efficacious for most individuals for the short-term reduction of ADHD 
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symptoms (Castellanos & Tannock, 2002b).  Both methylphenidate and amphetamine increase the 
amount of dopamine in the synapse through somewhat different mechanisms.  Methyphenidate blocks 
the reuptake of DA by the DA transporter, while amphetamine causes the DA transporter to be 
internalized (Saunders et al., 2000).  Blocking the DA transporter and decreasing the number of DA 
transporters results in the increase of dopamine within the synapse (Kuczenski & Segal, 1997; Segal & 
Kuczenski, 1999; Volkow et al., 2002).  Stimulants differentially increase dopamine release in the 
prefrontal cortex with minimal effects on subcortical brain regions (Berridge et al., 2006).  This increase 
in synaptic levels of DA, in turn, is believed to enhance executive functioning by way of frontostriatal 
pathways (Swanson, Kinshourne, Nigg, Lanphear, Stefanatos, et al., 2007).  The use of stimulant 
medication in the psychopharmacological treatment of ADHD and the involvement of the DA pathway in 
the mechanism of action of stimulants implicate DA as a possible source of ADHD pathophysiology, and 
has led to considerable interest in studying DA system genes as candidates for explaining the genetic 
basis of ADHD. 
There are multiple points of interest along the DA pathway which can be implicated in the 
etiology of ADHD, and research has focused on several genes involved in the regulation of DA.  One 
often studied candidate gene is the dopamine 4 receptor gene (DRD4).  The DRD4 gene has several 
alleles, which present in distinct variable number tandem repeat (VNTR) polymorphisms.  The most 
prevalent are the 2, 4 and 7-repeat alleles.  Research has primarily focused on the 7-repeat allele of 
DRD4, which has been hypothesized to increase the risk for ADHD (Faraone, Doyle, Mick & Biederman, 
2001).  Functionally, the 7-repeat allele results in a receptor, which is less sensitive to DA, reducing the 
formation of cyclic AMP (Asghari et al., 1995).  Results of studies examining the associations between 
the 7-repeat allele and ADHD have not been consistent, and no single study has indicated a significant 
association between the 7-repeat allele and ADHD.  Nevertheless, when results of multiple studies were 
pooled, an overall significant, but small effect, was noted.  The odds ratio (OR) for case-control studies 
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was 1.9 (p < 0.001), and for family-based studies was 1.4 (p = 0.02) (Faraone et al., 2005).  Other DRD4 
polymorphisms, the 2 and 4-repeat allele, have not demonstrated conclusive results (Kustanovich et al., 
2003).  Although far from conclusive, results implicate the DRD4 7-repeat allele as a possible contributor 
to the etiology of ADHD. 
Also of potential interest is the dopamine receptor 5 (DRD5) gene.  This receptor stimulates 
adenylyl cyclase activity and is expressed in the limbic system of the brain.  The limbic system is involved 
in motivation and emotion, and is regulated by the prefrontal cortex (Kustanovich, et al., 2003).  Results 
from studies examining the association between DRD5 and ADHD have been inconsistent.  Among three 
alleles of interest, 148-bp, 136-bp, and 146-bp alleles, one study revealed an association with the 148-bp 
allele, but not the 136-bp and 146-bp alleles (Barr et al., 2000).  Similarly, two family-based studies of 
association identified the 148-bp to be associated with ADHD (Payton et al., 2001).  Four meta-analyses 
indicated inconsistent results.  Two indicated an association with the 148-bp allele and ADHD with an 
(OR)=1.3 (Li, Sham, Owen, & He, 2006a; Lowe et al., 2004).  The remaining two meta-analytic studies did 
not find a relationship between the 148-bp allele and ADHD (Mill et al., 2005; Loo et al., 2003).  Taken 
together, one allele of the DRD5, the 148-bp allele, may be a source of possible association with ADHD, 
but further investigation is needed.  
 Studies exploring the relations between the dopamine D2 receptor gene (DRD2) and ADHD have 
focused on the A1 allele.  Imaging results indicate that individuals with the DRD2 A1 allele compared to 
those who do not have the allele, have a reduction in the number of D2 dopamine receptors and altered 
binding characteristics (Thompson et al., 1997).  The reduction in the number of D2 dopamine receptors 
results in a decrease in various complex cognitive functions (Noble, 2003).  One study supported the 
association between the A1 allele and ADHD, with a positive relationship such that increased frequency 
of the A1 allele was linked to greater severity of ADHD (Comings et al., 1996).  In contrast, another study 
found that a higher number of ADHD symptoms were associated with a decrease in the frequency of the 
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A1 allele, while a positive correlation was found between the A2 allele and symptoms of hyperactivity 
and impulsivity (Rowe, 1999).  Although a possible source of association with ADHD, findings involving 
DRD2 are inconsistent. 
The Dopamine D1 Receptor (DRD1) is expressed in multiple brain areas with high expression in 
the prefrontal cortex and striatum (Jin, Wang & Friedman, 2001).  DRD1 is implicated in multiple 
physiological functions such as regulation of neural growth and development (Arnsten, 2006; Paul, 
Graybiel, David, & Roberston, 1992) in addition to regulating hyperactivity (Crawford, Drago, Watson, & 
Levine, 1997) and attention (Arnsten, 2006).  Two different case control samples found an association 
with DRD1 in childhood combined type ADHD, but not in adulthood ADHD (Ribasés et al., 2012).  Bobb 
and colleagues (2005) found only two SNP alleles of the DRD1 gene to be significantly associated with 
ADHD (rs4532, rs265981).  
Other genes in the DA pathway have also been investigated as possible sources of ADHD 
heritability.  The dopamine transporter gene (DAT1) has been identified as a possible candidate due to 
stimulant medication’s mechanism of action of blocking the dopamine transporter (Spencer et al., 
2012).  Although one study found a significant association between DAT1 and the severity of ADHD 
symptomology, most studies have failed to show association of DAT1 and ADHD, (Faraone et al., 2005; 
Waldman et al., 1998; Franke et al., 2009; Spencer et al., 2012).  Dopamine beta hydroxylase (DBH) is 
the enzyme in the dopamine pathway, which converts dopamine to norepinephrine.  The A1 and A2 
alleles of the Taq 1 polymorphism of DBH were weakly but significantly associated with ADHD (Daly et 
al., 1999; Roman et al., 2002; Smith et al., 2003).  A small number of studies investigating the association 
of Tyrosine Hydroxylase (TH), the enzyme involved in the synthesis of DA, with ADHD have not observed 
any associations (Faraone et al., 2005).  Additionally, the dopamine D3 receptor (DRD3) has not been 
associated with ADHD (Brookes et al., 2006; Faraone et al., 2005; Guan et al., 2008).  Overall, although 
theoretically linked to ADHD via the mechanism of action of stimulant medications, studies of genes 
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involved in the DA pathway have not been successful in consistently identifying specific genes in the DA 
pathway, which are implicated in the heritability and etiology of ADHD. 
Other genes involved in the catecholaminergic system have also been studied in relation to 
ADHD.  Catechol-O-methyltransferase (COMT) is involved in the degradation of catecholamines, such 
as dopamine, epinephrine, and norepinephrine.  Association with ADHD has been inconsistent, with 
some studies showing significant association with the Val108Met polymorphism while other studies did 
not show significant associations (Faraone et al., 2005).  Monoamine Oxidase A (MAO-A) is an enzyme 
involved in the degradation of norepinephrine, dopamine, and serotonin.  Studies have shown 
association with ADHD for the 30-bp tandem repeat of the promoter region of the gene in two ethnic 
populations (Manor et al., 2001).  Similar to DA genes, results of studies focusing on the associations 
between other catecholaminergic system genes and ADHD are weak and inconsistent.   
Noradrenergic (NA) System Genes 
 In addition to the suggestion of a role for the DA pathway in the etiology of ADHD, 
pharmacological and neuroimaging studies also suggest the influence of the NA system.  Besides acting 
on DA, pharmacological interventions for ADHD also influence the noradrenergic system.  Not only do 
the stimulant medications have direct effects on central NA transmission that are analogous to their 
effects on DA, but atomoxetine, an effective nonstimulant, inhibits the presnaptic NA transporter, 
causing an increase in the release of monomaines (Popper, 2000).  Further, guanfacine, another non-
stimulant preparation approved for the treatment of ADHD, is a highly selective Alpha-2a agonist.  Thus, 
all medications that are effective for the treatment of ADHD have direct effects on the central NA 
system.  In addition to the pharmacological evidence, the NA system has important influences on the 
prefrontal cortex (Asghari, et al., 1995; Berridge, et al., 2006), and the ascending NA pathways from the 
brainstem to the prefrontal cortex play a role in executive functioning (Arnsten, 2006) and have been 
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demonstrated to be responsible for maintaining alertness and attentional control (Aston-Jones, 
Rajkowski & Cohen, 1999). 
The three most investigated NA genes associated with ADHD are the noradrenaline transporter 
(SLC6A2/NET1) and the three adrenergic receptors (ADRA1A, ADRA1B, and ADRA2B).  An international 
study of 51 candidate genes associated with ADHD reported a positive association with three NA system 
genes: SLC6A2/NET1, ADRA1A and ADRA2B (Brookes et al., 2006).  A subsequent meta-analysis did not 
find the same associations (Gizer, Ficks, & Waldman, 2009).  Most recently, a 91 SNP investigation by 
Hawi and colleagues (2013a) did not find a significant association with SLC6A2/NET1, ADRA1A, ADRA1B 
or ADRA2B genes; however significant associations with multi SNP haplotypes of SLC6A2/NET1 and 
ADRA1B were found.  These significant haplotype findings suggest a contribution of the NA system to 
the etiology of ADHD, with a call for further investigation. 
Studies investigating NA transporter and receptor SNPs in relation to ADHD have revealed 
inconsistent results.  Two studies found an association of a single SLC6A2 SNP (rs3785157), while only 
one study found an additional SNP association (rs998424) (Xu et al., 2005a; Bobb et al., 2005).  However, 
Brookes and colleagues (2006) failed to replicate the same positive results; in contrast two additional 
SNPs were found to be significant (rs3785143 and rs11568324).  While one study found a significant 
association between the G-1291C allele at the promoter region of the ADRA2A and ADHD (Comings et 
al., 2003), other studies failed to find the same associations (Xu et al., 2001; Roman et al., 2003; Park et 
al., 2004; Stevenson et al., 2005; Wang et al., 2006; Deupree et al., 2006).  Similarly, results are 
inconsistent when examining the relations with ADHD symptom dimensions.  However, Schmitz and 
colleagues (2006) found an association with the G-1291C allele exclusively in individuals with the 
Inattentive Subtype of ADHD.    
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Serotonergic System Genes 
 Although not as extensively investigated in the etiology of ADHD as catecholaminergic 
neurotransmitter systems, evidence suggests that serotonergic activity is associated with impulsivity, a 
key component of ADHD symptomatology (Oades, 2007).  In addition, evidence suggests an interaction 
between the serotonin and DA pathways, which regulates levels of both serotonin and DA (Oades, 
2007).  Therefore, a strong theoretical case can be made for a role for serotonin in the etiology of ADHD, 
with a particular association with impulsivity.   
 Research on the role of serotonin in the genetic etiology of ADHD has largely focused on four 
receptors (HTRIB, HTR2A, HTR1E and HTR3B).  Three studies found a significant association of the HTR1B 
receptor G861C allele with ADHD (Hawi et al., 2002; Quist et al., 2003; Smoller et al., 2006).   A later 
study did not find the same association (Heiser et al., 2007).  The T102C and G1438A polymorphisms of 
the HTR2A receptor have not been found to be significantly associated with ADHD (Zoroğlu et al., 2002).  
Results of two family-based studies revealed conflicting findings, one study found an association for only 
the His452Tyr allele and not the T102C allele (Quist et al., 2000) while another study did not find an 
association with either of these alleles (Hawi et al., 2002).  No significant associations were found with 
the HTR1E and HTR3B receptors (Brookes et al., 2006). 
The serotonin transporter has also been investigated as a source of ADHD etiology.  The 5-
HTTLPR polymorphism located in the promoter region of the serotonin transporter gene (SLC6A4) has 
been associated with ADHD in three case-control studies (Seeger, Schloss & Schmidet, 2001; 
Retz,Thome, Blocher, Badder & Rösler, 2002; Zoroğlu et al., 2002), with one study not finding an 
association (Beitchman et al., 2003).  One family- based study found an association between the 5-
HTTLPR polymorphism and ADHD (Kent et al., 2002), while another study found an association with only 
the combined type of ADHD (Manor et al., 2001).  A third study did not find any association (Cadoret et 
al., 2003).  Family based studies failed to identify an association with the promoter allele (Banerjee et 
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al., 2006; Kim et al., 2005; Li et al., 2007b; Xu et al., 2005b).  In addition to the investigation of the 5-
HTTLPR allele of the promoter region, an intron polymorphism has also been investigated.  One study 
found a negative association with the allele (Banerjee et al., 2006), six studies found no association 
(Brookes et al., 2006; Heiser et al., 2007; Kim et al., 2005; Wigg et al., 2006; Xu et al., 2005b), and Li and 
colleagues (2007b) found a positive association.  
 The last area of interest in the serotonin pathway is tryptophan hydroxylase (TPH).  TPH is a 
rate-limiting enzyme, which synthesizes serotonin from tryptophan.  Polymorphisms of TPH have been 
associated with aggression and impulsivity (Manuck et al., 1999).  Although two family-based studies did 
not find an association between ADHD and the TPH gene, one study found an under transmission of a 
haplotype consisting of two alleles in ADHD (Li et al., 2006b; Tang et al., 2001).  A family-based study 
found significant positive associations with three alleles; the rs1843809 T-allele, rs1386497 A-allele, and 
rs1386493 C-allele (Sheehan et al., 2005).  Brookes and colleagues (2006) also found positive 
associations with ADHD, although for rs1843809 A-allele and rs1386493 G-allele.  An association with 
rs1007023 was not found by Sheehan et al. (2005).  Overall, findings of associations between serotonin 
system genes and ADHD suggest potential sources of genetic etiology, but further investigation is 
warranted to clarify the findings. 
Genes involved in neural plasticity and development 
Due to evidence that ADHD is related to delayed brain growth and development (Shaw et al., 
2007), genes involved in neuronal growth and development have been theorized to play a role in the 
pathophysiology of ADHD.   
 Synaptosomal-associated protein 25, kDA (SNAP25) is a protein found in the presynaptic plasma 
membrane that is involved in the regulation of vesicular neurotransmitter release.  SNAP25, in 
combination with other proteins, forms a protein complex that is responsible for vesicle docking and 
adhesion at the presynaptic membrane which triggers neurotransmitter exocytosis from the presynaptic 
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membrane (Söllner et al., 1993).  SNAP25 is also important for axonal growth and synaptic plasticity 
(Osen-Sand et al., 1993).  A mouse model with a deletion in the gene that encodes SNAP25 leads to 
hyperactivity in the mice, along with compromised Ca++ dependent DA release in the dorsal striatum 
(Wilson, 2000).  Four family-based studies have examined two SNPs (T1069C and T1065G) in relation to 
ADHD.  Barr et al. (2000) found an association with the haplotype of the two alleles, while Kustanovich 
and colleagues (2003) were not able to find the same association.  Two studies with overlapping samples 
found marginal associations (Mill et al., 2002; Mill et al., 2004).  Pooled analysis for the T1065G SNP 
showed significant evidence for an association with ADHD (Mick & Faraone, 2008).  Analysis of two 
family-based studies, indicated association with four out 12 of SNPs (rs66039806-C, rs362549-A, 
rs362987-A, and the rs362998-C alleles) with one cohort, but not another cohort (Feng et al., 2005).  
Although Brookes and colleagues (2006) did not evaluate the same SNPs as the previous study, 
association with ADHD was found with rs363020 and rs362567.  Analysis of the previously associated 
SNPs in addition to five additional SNPs (rs6077699, rs363006, rs362549, rs362987, rs362998) found no 
evidence of association with ADHD for any of the alleles (Kim et al., 2007).  Moreover, pooled data 
indicated modest association with two SNPs (rs3746544-T, rs6077690-T) (Kim et al., 2007).  Expression 
analysis indicated a significant association with one SNP (rs362990-A) and a haplotype of three SNPs 
(rs6108461, rs362990 and rs362998) (Hawi et al., 2013b).  Evidence implicated specific SNPs from 
SNAP25 as being associated with ADHD.  
 One area of investigation has been the gene for brain-derived neurotrophic factor (BDNF), a 
protein that is involved in the survival and differentiation of dopaminergic neurons in the developing 
brain in addition to the stimulation of neuronal growth and differentiation.  The Val66Met functional 
polymorphism of the BDNF gene impacts intracellular trafficking and is involved in the activity-
dependent secretion of BDNF (Egan et al., 2003).  Kent and colleagues (2005) found an association 
between ADHD and paternal transmission of the Val66 allele of BDNF but not maternal transmission of 
NEURODEVELOPMENTAL GENES ADHD     14 
the same allele.  Xu and colleagues (2007) were not able to find the same results; in two family-based 
studies they found an over transmission of a different allele, the C720T allele, in only one family cohort.  
In contrast to the positive findings of the previous investigations, Brookes and colleagues (2006) failed 
to find significant associations in 20 BDNF SNPs.  Theoretically BDNF-related genes appear to be a 
promising direction of research, although supportive evidence at this point is lacking.    
Glutamate-related genes 
 Another area of investigation has involved glutamate receptors.  Glutamate and N-methyl- 
D-aspartate (NMDA) receptors have been associated with cognition.  A SNP of the glutamate receptor, 
ionotropic, N-methyl D-aspartate 2A (GRIN2A) gene has been associated with ADHD in a family-based 
study (Turic et al., 2004).  Haplotype associations with additional SNPs in the same study were weak.  A 
subsequent family-based study found no association with the GRIN2A SNP or two novel SNPs (Adams et 
al., 2004).  Similar to the results of BDNF, this area is theoretically promising, but results are inconsistent 
and need further investigation.  
Genome-wide Association Studies 
In contrast to hypothesis-driven studies of candidate genes, Genome-Wide Association Studies 
(GWAS) investigate common genetic variants in the entire genome of individuals and relate those 
variants to a specific trait.  Investigations utilizing the GWAS approach focus on associations between 
individual SNPs and ADHD.  Neale and colleagues (2010) were the first to conduct a case-control GWAS 
study on children and adolescents with ADHD.  Of the over one million SNPs, which were analyzed in the 
study, none met statistical significance.  One of the SNPs located in the Protein Kinase, CGMP-
Dependent 1 (PRKG1) gene was the closest to reaching significance.  Results from a case-control GWAS 
study conducted by Hinney et al. (2011) were similar, no SNP reached genome wide significance.  A SNP 
located on the Metabotropic Glutamate Receptor 5 (GRM5) gene was the best candidate for association.  
A subsequent GWAS again did not find any significant associations, but the Cholinergic Receptor, 
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Nicotinic, Alpha 7 (CHRNA7) receptor, was found to be the most promising (Stergiakouli et al., 2012).  
Three family-based GWAS studies found no significant genome results (Neale et al., 2008; Lasky-Su et 
al., 2008; Mick et al., 2010).  Although results did not reach significance, both Lasky-Su et al. and Mick et 
al. found SNPs associated with SLC9A9, an endosomal membrane protein gene involved in synaptic 
transmission and plasticity, to be the closest to reaching significance.  A large combined case-control 
and family-based study also failed to find genome wide significance (Neale et al., 2010).  Ebejer and 
colleagues (2013) performed a meta-analysis of GWAS studies using the inattention and hyperactivity 
symptom domains as continuous measures in the analysis.  Although the methodological approach was 
novel, results were similar to previous the GWAS studies, failing to show significant associations.   
More recent GWAS studies have taken different approaches to find an association with ADHD.  
In a departure from a typical GWAS approach that is not hypothesis driven, Bralten and colleges (2013) 
showed an association between the three pathways of dopamine/norepinephrine, serotonin, and 
neuritic out-growth genes and hyperactive/ impulsive symptoms and not inattentive symptoms. 
Findings were not significant for multiple single gene SNPs, suggesting that the combined small effects 
of multiple gene variants.  Due to limited data from genome association studies it has been suggested 
that biological processes such as, cell division, cell adhesion, neuronal migration, neuro plasticity, and 
transcription, and the genetic processes that are involved in these processes are likely to be involved in 
ADHD, in contrast to or in addition to dopaminergic, noradrenergic and serotonergic neurotransmitter 
(Franke, Neale & Faraone, 2009).  Like prior studies, a recent GWAS did not find genome-wide significant 
SNPs associated with ADHD symptoms, however, there were three genes with high linkage detectability, 
LMOD2, ASB15, and WASL (Middeldorp et al., 2016).  One of the genes, WASL, is involved in cytoskeletal 
organization during neuronal development, including long spine formation and neurite extension, which 
seems to be the likely gene associated with ADHD.  To increase the number of subjects Faraone (2016) 
combined data sets from multiple studies using only participants of European decent.  Analysis indicated 
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significance with FOXP2, which has been shown to be associated with cognitive functioning, 
development of language and speech, and expressed in the basal ganglia and inferior frontal cortex.  A 
GWAS study of glutamate genes indicated an association with hyperactivity/impulsivity severity, and 
GABA genes were associated with inhibition, but only when corrected for genome-wide association 
levels.  It is important to note that a single gene was not found to be significant but rather gene sets in 
tandem (Naaijen, et al., 2017). 
 An analysis of copy number variants (CNV) associated with biological pathways involved in 
neurodevelopment were significant for respiratory electron transport, organonitrogen compound 
catabolic process, transmembrane transporter activity, carbohydrate derivative catabolic process, 
ligand-gated ion channel activity, ligand-gated ion channel activity, transmembrane transport, and ion-
gated channel activity (Thapar et al., 2016).  This further supports evidence for continued investigation 
into neurodevelopmental pathways.  
Summary of Genetic Findings and Conclusions 
There are several possible explanations for the lack of positive and consistent molecular genetic 
results in ADHD studies.  One possibility is that ADHD is caused by single rare gene alleles, which have a 
major determining effect on the likelihood of ADHD psychopathology.  This possibility seems unlikely 
given the prevalence of ADHD.  Conversely, ADHD could be the result of multiple genes of very small 
effect size with ADHD being the result of multiplicative gene effects or gene x gene interactions.  Were 
either of these the case, conventional approaches to genetic analysis would be unlikely to detect specific 
genes related to the etiology of the disorder.  Alternatively, it seems increasingly likely that ADHD is the 
result of multiple etiologic pathways (Nigg, Willcutt, Doyle & Sonuga-Barke, 2005; Nigg, Nikolas, 
Knottnerus, Cavanagh & Friderici, 2010; Sonuga-Barke, 2005).  If this is the case and ADHD is 
etiologically heterogeneous, attempting to gain an understanding of specific genes involved in the 
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etiology of the disorder poses analytical difficulties and requires novel approaches to gene 
identification.  Summary of genetic findings can be located on Table 1 in the Appendix. 
In contrast to conceptualizing ADHD as a unitary disorder based solely on meeting diagnostic 
criteria for the disorder (yes/no), or even as distinct symptom dimensions of inattention and 
hyperactivity/impulsivity, an alternative approach is to examine potential endophenotypes, which are 
likely to be less genetically complex.  Endophenotypes, the quantitative traits that impact an individual’s 
risk to develop a disorder, can be meaningful sources of ADHD genetic etiology (Almasy & Blangero, 
1998).  Individuals with ADHD demonstrate phenotypic heterogeneity in terms of symptom severity, 
mixture of symptoms, developmental course, comorbidity and cognitive performance.  This phenotypic 
variability may be the result of different genetic risks and etiological pathways.  Moreover, research 
focusing on endophenotypic refinement, such as cognitive performance, instead of more complex 
dichotomous diagnoses or behavioral symptom dimensions, may lead to more precise findings in more 
homogeneous subgroupings of the disorder.  
 Potential endophenotypes of ADHD based on aspects of executive functioning may mediate the 
relations between the genetic risk and ADHD symptomatology.  The literature suggests that between 30-
50% of children with ADHD have an executive function deficit (Loo et al., 2007; Nigg, Willcutt, Doyle, & 
Sonuga-Barke, 2005).  Executive functioning can include such neuropsychological constructs as working 
memory, attention, planning, organization, inhibitory control, mental flexibility, initiation and self- 
monitoring (Arnsten, 2006).  Evidence of dysfunction in frontostriatal pathways, which play a key role in 
executive functioning, has been reported in neuroimaging studies, eletrophysiological studies, and 
neuropsychological assessment (Seidman, Valera & Makris, 2005; Chabot & Serfontein, 1996; Willcutt et 
al., 2005). 
 In addition to its symptomatic and neurocognitive heterogeneity, ADHD also has tremendous 
heterogeneity regarding the developmental course and outcome.  One longitudinal study found that 
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approximately half of 3- and 4-year-old children who presented with behavioral difficulties no longer 
had symptoms at age 6 (Campbell, 1987).  Others who used more rigorous diagnostic criteria for ADHD 
found greater persistence from preschool to the school-age years, yet outcomes during childhood were 
highly variable (Lahey, Pelham, Loney, Lee & Willcutt, 2005).  This heterogeneity of course persists 
throughout the lifespan with anywhere from 22 – 65% of children with ADHD having persistence of 
symptoms into adolescence and adulthood (Barkley, Murphy, DuPaul & Bush, 2002; Biederman, Petty, 
Evans, Small & Faraone, 2010; Halperin, Trampush, Miller, Marks & Newcorn, 2008; Klein et al., 2012; 
Mannuzza et al., 2002).   
While most genetic studies of ADHD have focused on the onset (presence vs. absence) of the 
disorder or its associated symptoms, it has been hypothesized that the onset of ADHD and its 
subsequent developmental trajectory, in particular as related to persistence and remittance, involve 
distinct neural processes (Halperin & Schulz, 2006).  Consistent with this idea, preliminary data suggest 
that gene regulation might play a role in the divergent developmental trajectories of ADHD and that 
genetic risk for ADHD can contribute to the developmental stability of the disorder.  For example, Kuntsi 
et al. (2005) found that children with ADHD who also had the DRD4 7-repeat allele were less likely to 
persist with ADHD into middle childhood as compared to those without that allele.  Further, children 
with the 7-repeat allele had greater normalization of cortical thinning, higher IQ scores, and better 
global functioning compared to children with ADHD who did not have the 7-repeat allele (Kuntsi et al., 
2005).   
A British twin study found inter-individual differences in the developmental course of ADHD. 
Hyperactive/Impulsive symptom severity was mostly explained by strong additive genetic influences, 
while inattentive symptoms were associated with nonadditive genetic influence (dominant genetic 
influence) (Pingault et al., 2015).  This suggests that large genetic influences on the trajectory of ADHD 
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symptoms are mostly specific and independent of those that account for variation in the baseline level 
of symptoms. 
 Further, the developmental trajectory of ADHD may also be linked to gene expression.  DNA 
methylation, histone acetylation or methylation can regulate gene expression, which in turn influences 
transcription activity and ultimately downstream expression of the gene product (Li et al., 2007a).  Thus, 
it is possible for gene expression to have a developmental course, with gene transcription varying across 
development (Doyle et al., 2005).  In addition to transcription factors, posttranscriptional factors such as 
microRNAs are also involved in gene silencing (He & Hannon, 2004).  MicroRNA’s have been shown to 
regulate various developmental and physiological processes.  The differential trajectory of ADHD across 
development suggests that the role of gene regulation through external factors can play a role in the 
remittance or persistence of ADHD.  
 Current voids in the understanding of ADHD and the plethora of inconsistent and largely 
negative findings call for novel approaches to investigating the role of genes in ADHD.  Further, the 
dearth of studies that have considered the phenotypic heterogeneity or the role of development in this 
highly heterogeneous neurodevelopmental disorder is striking.  Clearly, further longitudinal research 
focusing on the relations between genes and the developmental course/trajectory of ADHD is 
warranted.  Considering the heterogeneity of this disorder, the assessment of mediators and 
moderators of the relations between genes and trajectory might yield particularly fruitful results.  
Focusing on genes regulating monoamines closely associated with ADHD and frontostriatal systems in 
the brain, such as the catecholamines, as well as brain growth and development might be a good place 
to start.  
Alternative Genetic Direction: Genes Associated with Neurodevelopment  
 As a developmental disorder, it is expected that genes associated with early neurodevelopment 
would have a substantial role in the etiology and/or the trajectory of ADHD.  Due to the absence of 
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strong molecular genetic associations in the presence of strong heredity a genetic proposal of 
alternative genes and SNPs is proposed.  Given that ADHD is most likely related to many genes of small 
effect size, it is likely that few or none of these genes alone will demonstrate a significant association 
with the disorder.  Rather, the combination of several genes might be more promising. 
Neuroregulin-1 
 Neuroregulin-1 (NRG1), a pleotropic growth and differentiation factor, contributes to the 
increase in the phosphorylation of tyrosine kinase (Falls, 2003).  Studies on the functionally of NRG1 
have observed that the gene is involved in the establishment and fine-tuning of cortical circuitry, and 
synaptic efficacy.  More specifically, in vitro studies demonstrated NRG1 to prompt the transcription of 
mRNAs encoding neurotransmitter receptors (Ozaki et al., 1997), to modulate glutamatergic, GABAergic, 
cholinergic, and dopaminergic neurotransmission (Gu et al., 2005; Ting et al., 2011; Woo et al., 2007), 
and to promote dendritic spine growth (Cahill et al., 2013).  Furthermore, dysregulation of expression 
impaired synaptic plasticity, and overexpression of Ig-NRG1 in mice lead to synaptic dysfunction and 
behavioral deficits, which included hyperactivity (Yin et al., 2013).  Both increased and decreased 
expression of the NRG1 has been associated with susceptibility to schizophrenia (Bertram et al., 2007; 
Law et al., 2006, Yang, et al., 2003).  NRG1 has been shown to be involved in multiple aspects of efficient 
and effective neuronal formation, and is associated behavioral outcomes.  
Neurotrophic factors: Neurotrophin-3 and Brain Derived Neurotrophic Factor 
 Neurotrophin-3 (NT-3) and Brain Derived Neurotrophic Factor (BDNF) are both essential for 
neural growth, survival, and differentiation, and are therefore crucial for brain development.  NT-3 and 
BDNF both play a neuroprotective role against glutamate toxicity and glucose deprivation and neuronal 
calcium homeostasis and protect neurons against metabolic/excitotoxic insults (Cheng & Mattson, 
1994).  Animal studies demonstrated that NT-3 and BDNF are expressed in the embryonic cortex, with 
NT-3 expression decreasing as maturation progresses.  In contrast BDNF is low in developing regions of 
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the cortex and increases with maturation of the region (Maisonpierre, et al., 1990).  Evidence shows that 
both BDNF and NT-3 are involved in regulating the dendritic growth of pyramidal neurons in layer 4 of 
the cerebral cortex, and NT-3 inhibits the dendritic growth stimulated by BDNF.  In contrast, in layer 6 of 
the cerebral cortex, BDNF inhibited dendritic growth stimulated by NT-3 (McAllister, Katz, & Lo, 1997).  
Neurotrophins have also been investigated as mechanisms of synaptic plasticity, and long-term 
functional and structural modification of synaptic connections (Poo, 2001).  Primary alterations in the 
activity of neurotrophins could lead to inappropriate alterations in cortical circuitry and synaptic 
transmission in the developing brain, which could then lead into the neuronal dysfunction which 
underlying psychiatric disorders such as schizophrenia (Favalli, Belmonte-de-Abreu, Wong, & Daskalakis, 
2012).  
 NT-3 has been demonstrated to be involved in regulating central nervous system neurogenesis, 
more precisely regulating aspects of early CNS development.  In vitro studies corroborate the effects of 
NT-3 on cell proliferation and differentiation, which are key regulators of neurogenesis in the CNS, which 
can result in neuronal differentiation (Ghosh & Greenburg, 1995).  A haplotype of NT-3 (rs4074967-
rs6332-rs6489630-rs7956189) was shown to be more associated with childhood ADHD compared to 
adulthood ADHD and control (Ribasés, et al., 2008).  NT-3 SNP rs6489630 has shown to be a protective 
factor for Alzheimer’s Disease (Liu et al., 2016). 
 BDNF is involved in neurodevelopment, synapse regulation, and synaptic plasticity, it has been 
proposed as a candidate to explain part of the pathogenesis of neurodevelopmental disease.  BDNF has 
been shown to modulate synaptic transmission (Levine, Dreyfus, Black, & Plummer, 1995).  Adult BDNF 
knockout mice have impaired hippocampal-dependent learning and long-term potentiation.  In early 
development, BDNF knockout mice exhibited hyperactivity and hippocampal learning deficits 
(Monteggia, et al., 2004).  BDNF SNP rs6265 has been shown to be involved in the pathophysiology of 
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mood disorders and schizophrenia (Fernandes et al., 2014), and associated with parental reports of 
ADHD symptoms (Gadow, et al., 2009).   
Regulator of G protein signaling 4  
 Although less investigated than the prior genes, Regulator of G protein signaling 4 (RGS4), has 
been implicated in dopamine expression and psychiatric illness.  Specially, RGS4 SNP (rs951439) is one of 
several SNPS being implicated in the clinical symptoms and antipsychotic treatment response of 
schizophrenia, identifying RGS4 as a gene that contributes to the susceptibility of the disorder (Ding, 
Styblo, Drobna, & Hegde, 2016).  It is posited that one of the ways that RGS4 contributes to the etiology 
is by influencing dopamine signaling, with RGS4 expression associated with cortical dopamine signaling 
with COMT Val158Met genotype being associated with prefrontal along with hippocampal RGS4 
expression (Lipska, 2006).  RGS4 expression in the dorsolateral prefrontal cortex can also inhibit 
dopamine D2 and D3 receptor signaling, while a decrease in RGS4 can increase D2 and D3 receptor 
signaling (Min, 2012).  Although there is not currently a direct link to suggest that RGS4 has a role in the 
etiology of ADHD, there is a theoretical associated between similar neurotransmitter pathways. 
Environmental Factors 
 In addition to genetic factors, several prenatal environmental factors have been shown to 
influence neurodevelopment with some factors being associated with the development of ADHD. 
Nicotine  
 Several studies have implicated prenatal nicotine exposure in the etiology of ADHD.  A meta-
analysis linked maternal and environmental nicotine exposure to signs of stress and nicotine withdrawal 
following birth, presence of ADHD, and other externalizing outcomes, such as rule breaking and 
aggressive behavior (Manzano et al., 2016).  A retrospective study determined that children with ADHD 
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were 2.1 times as likely to be exposed to nicotine during pregnancy compared to non-ADHD controls 
(Mick, Biederman, Faraone, Sayer, & Kleinman, 2002).  Additionally, a large Finish study revealed a 
significant increase in ADHD in individuals exposed to maternal tobacco smoking (Joelsson et al., 2016).  
Similarly, a large South Korean study of children born to mothers that smoked during pregnancy were 
2.64 times more likely to be diagnosed with ADHD (Han et al., 2015).  An investigation into the 
neurocognitive and behavioral outcomes of children exposed to maternal smoking during pregnancy 
showed lower verbal IQ, sluggish cognitive tempo on a measure of visual sustained attention (CPT), 
more externalizing behaviors, emotional lability, restlessness/impulsivity, and visual working memory 
deficiencies during school age (Thakur et al., 2013).  The level of neuropsychological impairment had a 
dose dependent impact.  A recent Western Australian study found maternal smoking to a be a risk factor 
for ADHD (Silva, Colvin, Hagemann, & Bower, 2013), and a large Danish study found that both maternal 
and paternal smoking was associated with ADHD risk, with maternal smoking posing a higher risk, even 
when the mother used nicotine replacement during pregnancy (Zhu et al., 2014).  In contrast to these 
studies Langley and colleges (2012) observed that both maternal and paternal smoking during 
pregnancy was associated with ADHD symptoms, suggesting that the association with ADHD might be 
more associated with heredity than prenatal environment. 
Alcohol 
Excessive maternal alcohol intake during pregnancy is associated with Fetal Alcohol Syndrome, 
facial dysmorphology, growth restriction, and central nervous system/neurodevelopmental 
abnormalities, which present as cognitive and social difficulties (Sokol, Delaney-Black, & Nordstrom, 
2008).  A Ukrainian study indicated that maternal alcohol consumption was associated with 
neurodevelopmental deficits at 6 and 12 months (Bandoli, et al., 2016).  A meta-analysis investigating 
mild, moderate, and binge alcohol exposure during pregnancy found that binge consumption had a 
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negative impact on cognition, and a moderate association with child behavior (Flack, 2013).  Maternal 
alcohol use during pregnancy was associated with increased ADHD risk 1.55 times, compared to mothers 
that did not use alcohol during pregnancy (Han, et al., 2014).  Children diagnosed with ADHD were 2.5 
times as likely to be exposed to alcohol during pregnancy compared to non-ADHD controls (Mick, 
Biederman, Faraone, Sayer, & Kleinman, 2002). 
Illicit Drug Use  
 Research into maternal illicit drug use during pregnancy is limited, and due to the nature of the 
substances used, are likely to be underreported.  Nevertheless, literature on cannabis use during 
pregnancy indicates adverse effects on neurodevelopment, especially during critical periods of brain 
growth during fetal and adolescent maturation, such that children have long-term difficulties with visual 
memory, executive functioning progressing through adolescence with aggression and attention 
problems reported in preschool age children (Jaques et al., 2014).  Children ages 1 and 3 with prenatal 
exposure to methamphetamine had lower gross motor functioning, but not lower cognitive functioning 
(Wouldes et al., 2014).  Cocaine exposure during pregnancy has been associated with attention 
difficulties in preschool and school age children (Leech, Richardson, Goldschmidt & Day, 1999; Bandstra, 
Morrow, Anthony, Accornero, & Fried, 2001; Arendt, et. al, 2004; Savage, Brodsky, Malmud, Giannetta, 
& Hurt, 2005).  Illicit drug use in pregnancy has many confounds associated with the research.   
Nevertheless, current literature does suggest long-term cognitive and behavioral effects associated with 
exposure. 
Maternal Gestational Diabetes 
Maternal gestational diabetes has also been shown to be associated with ADHD.  A 
computerized measure of inattention, vigilance and perseveration (Conners CPT-II), did not show 
differences.  However, individuals born to women with gestational diabetes, were shown to have more 
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psychopharmacological medication use for ADHD (Bytoff et al., 2017).  A study following children born 
to mothers with gestational diabetes, at 18-months had lower gross motor and expressive language 
functioning (Torres-Espinola et al., 2015).  A study of early infant development indicated that at 6 and 
18-months there was greater inattention as indicated using an ERP paradigm (Cai et al., 2016).  School 
age children born to mothers with gestational diabetes showed fine and gross motor impairments and 
difficulties with attention (Ornoy, Ratzon, Greenbaum, Wolf & Dulitzky, 2001).  However, findings are 
not consistent where one study showed that maternal obesity was associated with increases risk for 
ADHD in preschool, maternal gestational diabetes was not (Daraki et al., 2017).  Nomura and colleagues 
demonstrated that maternal gestational diabetes and low SES accounted for a 2-fold increase in ADHD 
diagnosis at 6 years (2012). 
The Present Study 
 The aim of the current study is to examine the moderating effects of gene polymorphism on the 
developmental trajectory of ADHD using hierarchical linear modeling.  Participants in the current study 
are a part of a larger established longitudinal study which has followed and evaluated children annually 
from preschool to school age.  During these annual evaluations, beginning at age 3-4 and continuing 
until age 10, a parent diagnostic interview was conducted to determine ADHD symptom severity.  The 
moderating effects of four single nucleotide polymorphisms (SNPS) associated with neurodevelopment 
and/or psychopathology were examined: neuregulin-1 (NRG-1; rs3924999), neurotropin-3 (NT-3; 
rs6489630), brain-derived neurotrophic factor (BDNF; rs6265), and regulator of G protein signaling 4 
(RGS4; rs951439).  By using a novel longitudinal approach, rather than a single time point, allowed for a 
more complete understand of the heterogeneity in the developmental trajectory of the disorder.  
 Taking reference from Rutter (1987) and the impact of psychosocial risk factors and the 
interactive process of these factors on development, the current study examined the impact of prenatal 
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environmental risk factors on ADHD symptom severity with the moderation of the chosen gene 
polymorphisms and the prenatal environmental risk factors of maternal gestational diabetes, maternal 
tobacco, alcohol and illicit drug use during pregnancy were examined.   
Hypotheses 
It was hypothesized that at risk-alleles of NRG-1, NT-3, BDNF, and RGS4, would be associated 
with ADHD symptoms at preschool age.  Additionally, it was hypothesized that the risk-alleles of NRG-1, 
NT-3, BDNF, and RGS4 would be associated with persistence of ADHD symptoms until school age.  
Finally, prenatal environmental factors (maternal gestational diabetes, maternal nicotine, alcohol and 
illicit drug use) were explored as moderating factors of ADHD symptom severity at preschool age and at 
school age.  
METHOD 
Participants 
 As part of larger longitudinal study examining factors associated with the persistence of ADHD 
symptoms in preschoolers, a community-based sample of 3- and 4-year-old children were recruited.  At 
the initial recruitment permission form principals of local preschools was obtained to screen the school 
for children with attention and behavior problems.  Additional referrals from schools and clinicians were 
also accepted.  Entry into the study was based on parent and teacher reports on the home and school 
version of the Attention-Deficit/Hyperactivity Disorder Rating Scale, Fourth Edition (ADHD-RS-IV, 
McGoey, DuPaul, Haley, & Shelton, 2007).  Children who received 6 or more symptoms rated as “Often” 
or “Very Often” on the Hyperactivity/Impulsivity and/or Inattention subscale(s) either by parent or 
teacher were considered hyperactive/inattentive.  Children who received fewer than 3 items rated as 
“Often or Very Often” by both parents and teachers were expected into the study as Typically 
Developing.  Exclusion criteria were: Full Scale IQ < 80, as measured by the Wechsler Preschool and 
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Primary Scale of Intelligence-Third Edition (WPPSI-III; Wechsler, 2002); evidence of a Pervasive 
Developmental Disorder, Post-traumatic Stress Disorder or a diagnosed neurological disorder; non-
English-speaking parent or child; child not attending school; and treatment with systemic medication for 
a chronic medical condition (including ADHD).  The final sample for the longitudinal study was 216.  
Among those, genetic data were successfully collected for the participants in this study, which consisted 
of 145 children (109 boys) ranging in age from 3.00 to 4.92 years (M=4.22, SD=0.49) at the initial 
evaluation (T1) and ranging in age from 10.37 to 12.51 years (M=11.43, SD=0.51) at the final evaluation 
(T8).  Of the 71 that were not included in the analysis, 48 were boys ranging in age from 3.19 to 5.00 
(M=4.41, SD=0.44) at the first initial evaluation.  
 The sample was racially and ethnically diverse, comprising of 16 black (11.0%), 18 Asian (12.4%), 
25 Hispanic (17.2%), 25 more than one race (17.2%), and 61 (42.1%) white children.  Socioeconomic 
status was assessed by the Occupational Prestige Scale (Nakao & Treas, 1994); the sample was largely 
middle class (M=63.86, SD= 17.39) although a wide range was represented (range=20-97).  (Sample 
characteristic Table 2).  
This study was approved by the Institutional Review Board of the university in which the 
research was conducted.  Following a complete description of the study, a parent of each child provided 
written informed consent for participation. 
Measures 
 Primary caregivers were interviewed at the baseline assessment (T1) and then annually to the 
final measurement (T8) using the Kiddie Schedule for Affective Disorders and Schizophrenia – Present 
and Lifetime Version (Kiddie-SADS-PL; Kaufman, Birmaher, Brent, Rao, & Ryan, 1996).  The Kiddie-SADS-
PL is a commonly used diagnostic semi-structured interview that, when administered by trained 
evaluators, has been shown to have strong psychometric properties (Kaufman et al., 1999).  Diagnostic 
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questions on the K-SADS-PL correspond to the 18 ADHD symptoms of ADHD.  Each symptom was rated 
as either 0 (symptom was not present), 1 (subthreshold symptom) to 2 (symptom present at diagnostic 
level).  The total score from all 18 symptoms provided the value for Total ADHD symptom severity.  The 
score from the 9 inattentive symptoms provided the value for the Inattentive symptom severity.  The 
score for the remaining 9 hyperactive/impulsive symptoms provided the value for the 
Hyperactive/Impulsive symptom severity.  When available, teacher rating on the school version of the 
ADHD-RS-IV were incorporated to reach the final determination about each symptom at each time 
point.  
 At the time of the baseline evaluation the caregiver completed an early developmental history 
questionnaire that assessed prenatal risk factors.  The caregiver indicated the presence of the following 
during gestation: maternal gestational diabetes, maternal substance use (alcohol, tobacco, illicit drug 
use).  
Genotyping procedure 
Genomic DNA was extracted from saliva (oragene•DNA, DNA Genotek, Inc, Ottawa, Ontario, Canada) 
quantified on a spectrophotometer (NanoDrop ND-1000, NanoDrop, Wilmington, DE).  A 1 ng DNA was 
amplified in duplicate with a pre-designed TaqMan assay (assay ID C___1877332_20) according to the 
manufacturer’s instructions (Thermo Scientific, Waltham, MA) and identified by measuring end-point 
fluorescence on a LightCycler 480 II (Roche, Indianapolis, IN).  Genotypes were determined for four 
genes NRG1 (rs392499), NT-3 (rs6489630), BDNF (rs6265) and RGS4 (rs951439).  The number of risk 
alleles was calculated for each gene, and participants were categorized as either having no risk alleles or 
at least one risk allele (1 or 2 risk alleles).  A secondary analysis for the total number of risk gene alleles 
was completed for NRG1, NT-3 and BDNF.  
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Data Analysis 
Due to the longitudinal nature of the data, varied ages of participants at the initial time point, and 
missing values, Hierarchical linear modeling (HLM) was used at the primary statistical analysis.  The 
advantage of HLM is that it takes into account initial values beginning at different time points and 
missing values.  Therefore, in the current study, HLM can describe the growth curve of each individual’s 
trajectory of ADHD symptom severity, collected yearly, across an 8-year period.  HLM allows modeling 
both within-and between-individual variations.  At level-1, each individual’s data of ADHD symptom 
severity was fitted into a regression line.  Level-1 coefficients are empirical Bayesian estimates, which 
are optimal estimates based on data from the individual and the entire sample.  At level-2, the individual 
genetic risk factors were entered to explain the between-subject variation in the intercept and the liner 
slope.  
To evaluate the longitudinal trajectory of ADHD symptom severity, the level-1 model was 
defined, and then evaluated with level-2 predictors.  At level-1, the linear model was tested for ADHD 
symptom severity for three values: total, inattentive and hyperactive/impulsive symptoms.  After the 
level-1 model was determined, the genetic risk factors (for NRG-1, NTF3, BDNF, RGS4) were entered into 
the model as level-2 variables, to determine if they explained a significant amount of the variance in the 
mean intercept or slope.  The intercept corresponded to the level of ADHD symptoms at the initial time 
point, while the slope corresponded to change in ADHD symptom trajectory over the 8 time points.  
To evaluate the impact of early prenatal environmental factors, a secondary analysis employed 
independent samples t-tests to explore significant differences on ADHD Total symptom severity at the 
final time point (T8).  Lastly, regression analyses were used for the early environmental risk factors 
(maternal gestational diabetes, maternal substance use (alcohol, tobacco, illicit drug use) in conjunction 
with NRG-1, NTF3, and BDNF alleles.   
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Table 2: Race and Ethnicity Characteristics  
 Frequency (%)  
White 86 (59%) 
Asian 18 (12%) 
Black 16 (10%) 
Other/Mixed 25 (17%) 
Total 145  
     Not Hispanic 104 (72%) 
     Hispanic  41 (28%) 
 
RESULTS 
I. Gene Main Effects  
Change in Total ADHD Symptom Severity  
As shown in Table 3 and depicted in Figure 1, the estimated mean Total ADHD Symptom 
Severity at 3-4 years was 17.08 (SE=0.94).  The average slope or rate of change in ADHD severity over 
time was -0.10 (SE=0.10).  There was significant estimated variation around the intercept (χ2 = 1107.99, 
df=144, p<0.001) and the slope (χ2 = 369.94, df=144, p<0.001).  This indicates that the children varied 
significantly in their Total ADHD Symptom Severity at age 3-4 and in their rate of change in Total ADHD 
Symptom Severity over time.  
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TABLE 3: Change in Total ADHD Symptom Severity over time 
Results             Analysis    
Fixed Effects    Coefficient  SE  T ratio  p 
Level 1 intercept 
  Intercept    17.08   0.94  18.15  <0.001 
Level 1 linear slope 
  Intercept    -0.10   0.10  -0.96  0.34 
 
Random Effects   Variance Component    df  χ2      p 
  Level 1 intercept   112.22   144  1107.99 <0.001 
  Level 1 linear slope       0.98   144  369.94  <0.001  
 
FIGURE 1 
Model 1: Trajectories of Total ADHD Symptom Severity from ages 3 to 11 years.  
 
 
Figure 1:  The model is centered at the baseline age, 3-4 years, which is indicated as 0 on the x-axis.  The 
y-axis indicates total ADHD symptom severity.  
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Change in Inattentive Symptom Severity  
As shown in Table 4 and depicted in Figure 2, the estimated mean Inattentive Symptom Severity 
at 3-4 years was 7.24 (SE=0.46).  The average slope or rate of change in Inattentive Symptom severity 
was 0.28 (SE=0.06).  There was significant estimated variation around the intercept (χ2 = 727.26, df=144, 
p<0.01) and the slope (χ2 = 338.81, df=144, p<0.001).  This Indicates that the children varied significantly 
in their Inattentive Symptom severity at age 3-4 and in their rate of change in Inattentive Symptom 
severity over time.  
TABLE 4: Change in Inattentive Symptom Severity over time 
Results             Analysis    
Fixed Effects    Coefficient  SE  T ratio  p 
Level 1 intercept 
  Intercept    7.24   0.46  15.844  <0.001 
Level 1 linear slope 
  Intercept    0.28   0.06         4.69  <0.001 
 
Random Effects   Variance Component    df  χ2      p 
  Level 1 intercept   24.47   144  727.26  <0.001 
  Level 1 linear slope   0.54   144  338.81  <0.001  
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FIGURE 2: 
Model 1: Trajectories of Inattentive Symptom Severity from ages 3 to 11 years.  
 
Figure 2: The model is centered at the baseline age, 3-4 years, which is indicated as 0 on the x-axis.  The 
y-axis indicates Inattentive Symptom Severity.   
Change in Hyperactive/Impulsive Symptom Severity  
As shown in Table 5 and depicted in Figure 3, the estimated mean Hyperactive/Impulsive 
Symptom Severity at 3-4 years was 9.82 (SE=0.53).  The average slope or rate of change in 
Hyperactive/Impulsive Symptom Severity over time was -0.38 (SE=0.06).  There was significant 
estimated variation around the intercept (χ2 = 1165.16, df=144, p<0.01) and the slope (χ2 = 393.09, 
df=144, p<0.001).  This Indicates that the children varied significantly in their Hyperactive/Impulsive 
Symptom Severity at age 3-4 and in their rate of change in Hyperactive/Impulsive Symptom Severity 
over time.  
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TABLE 5: Change in Hyperactive/Impulsive symptom severity over time 
Results             Analysis    
Fixed Effects    Coefficient  SE  T ratio  p 
Level 1 intercept 
  Intercept     9.82   0.53  18.40  <0.001 
Level 1 linear slope 
  Intercept    -0.38   0.06       -6.38  <0.001 
 
Random Effects   Variance Component    df  χ2      p 
  Level 1 intercept   36.32   144           1165.16  <0.001 
  Level 1 linear slope     0.57   144  393.09  <0.001  
FIGURE 3: 
Model 1: Trajectories of Hyperactive/Impulsive Symptom Severity from ages 3 to 11 years.  
 
Figure 3: The model is centered at the baseline age, 3-4 years, which is indicated as age 0 on the x-axis.  
The y-axis indicates Hyperactive/Impulsive Symptom Severity.  
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Neuroregulin-1 (NRG1) 
Association of NRG1 risk allele with Total ADHD symptom severity over time  
 As shown in Table 6 and depicted in Figure 4, the estimated mean of Total ADHD symptom 
severity at age 3-4 years in children without the NRG1 risk allele was 11.08 (SE=2.00), with a significant 
increase of 7.31 (SE=2.25) with at least one NRG1 risk allele (p<0.01).  The average slope or rate of 
change in Total ADHD symptom severity did not differ by NRG1 risk allele from age 3-4 years to age 11 
years (p=0.518).  There was significant variation around the average intercept (χ2=1030.20, df=143, 
p<0.001) and the average slope (χ2=368.45, df=143, p<0.001) that was not accounted for by the model.  
TABLE 6: Association of NRG1 risk allele with Total ADHD symptom severity over time 
Results             Analysis    
Fixed Effects   Coefficient  SE  T ratio  p 
Level 1 intercept 
  Intercept       11.08   2.00   5.53  <0.001 
  NRG1          7.31   2.25   3.25  <0.01 
Level 1 linear slope 
  Intercept        -0.26  0.28  -0.94  0.349 
  NRG1           0.20   0.30   0.65  0.518 
 
Random Effects   Variance Component        df  χ2      p 
  Level 1 intercept   105.34     143  1030.21 <0.001 
  Level 1 linear slope       0.98     143  368.45  <0.001  
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Figure 4: Association of NRG1 risk allele with Total ADHD symptom severity over time 
 
 
Figure 4: The model is centered at the baseline age, 3-4 years, which is indicated as age 0 on the x-axis.  
The y-axis indicates total ADHD Symptom Severity.  Red line indicates at least one risk allele for NRG-1, 
while the blue is no risk alleles for NRG-1.  
Association of NRG1 risk allele with Inattentive symptom severity over time 
 As shown in Table 7 and depicted in Figure 5, the estimated mean of Inattentive symptom 
severity at age 3-4 years in children without the NRG1 risk allele was 4.82 (SE=0.94), with a significant 
increase of 2.95 (SE=1.06) with at least one NRG1 risk allele (p<0.01).  The average slope or rate of 
change in Inattentive symptom severity did not differ by NRG1 risk allele from age 3-4 years to age 11 
years (p=0.250).  There was significant variation around the average intercept (χ2=689.6.20, df=143, 
p<0.001) and the average slope (χ2=333.40, df=143, p<0.001) that was not accounted for by the model.  
TABLE 7: Association of NRG1 risk allele with Inattentive symptom severity over time 
Results             Analysis    
Fixed Effects    Coefficient  SE  T ratio  p 
Level 1 intercept 
  Intercept        4.82   0.94   5.16  <0.001 
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  NRG1         2.96   1.06   2.79  <0.01 
Level 1 linear slope 
  Intercept         0.11   0.17   0.61  0.544 
  NRG1           0.21   0.18   1.65  0.250 
Random Effects    Variance Component        df  χ2      p 
  Level 1 intercept   4.84   143  689.61  <0.001 
  Level 1 linear slope   0.54      143  333.40  <0.001  
 
Figure 5: Association of NRG1 risk allele with Inattentive symptom severity over time 
 
Figure 5: The model is centered at the baseline age, 3-4 years, which is indicated as age 0 on the x-axis.  
The y-axis indicates Inattentive Symptom Severity.  Red line indicates at least one risk allele for NRG-1, 
while the blue is no risk alleles for NRG-1.  
Association of NRG1 risk allele with Hyperactive/Impulsive symptom severity over time 
 As shown in Table 8 and depicted in Figure 6, the estimated mean of Hyperactive/Impulsive 
symptom severity at age 3-4 years in children without the NRG1 risk allele was 6.25 (SE=1.11), with a 
significant increase of 4.35 (SE=1.26) with at least one NRG1 risk allele (p<0.01).  The average slope or 
rate of change in Hyperactive/Impulsive symptom severity did not differ by NRG1 risk allele from age 3-4 
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years to age 11 years (p=0.958).  There was significant variation around the average intercept 
(χ2=1078.79, df=143, p<0.001) and the average slope (χ2=392.99, df=143, p<0.001) that was not 
accounted for by the model.  
TABLE 8: Association of NRG1 risk allele with Hyperactive/Impulsive symptom severity over time 
Results             Analysis    
Fixed Effects    Coefficient  SE  T ratio  p 
Level 1 intercept 
  Intercept        6.25   1.12   5.60  <0.001 
  NRG1         4.35   1.26   3.46  <0.01 
Level 1 linear slope 
  Intercept         -0.38   0.13   -2.91  <0.01 
  NRG1           -0.01   0.14   -0.05  0.958 
Random Effects    Variance Component        df  χ2      p 
  Level 1 intercept   5.82   143  1078.79 <0.001 
  Level 1 linear slope   0.57      143  392.99  <0.001  
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Figure 6: Association of NRG1 risk allele with Hyperactive/Impulsive symptom severity over time 
 
Figure 6: The model is centered at the baseline age, 3-4 years, which is indicated as age 0 on the x-axis.  
The y-axis indicates Hyperactive/Impulsive Symptom Severity.  Red line indicates at least one risk allele 
for NRG-1, while the blue is no risk alleles for NRG-1.  
Neurotropin-3 (NT-3) 
Association of NT-3 risk allele with Total ADHD symptom severity over time 
 As shown in Table 9 and depicted in Figure 7, the estimated mean of Total ADHD symptom 
severity at age 3-4 years in children without the NT-3 risk allele was 16.57 (SE=1.17) with a 
nonsignificant increase of 1.45 (SE=1.97) in children with the at least one NT-3 risk allele (p=0.462).  The 
average slope or rate of change in Total ADHD symptom severity did not differ significantly by NT-3 risk 
allele from age 3-4 years to age 11 years.  However, there was a trend for rate of change as a function of 
NT-3 allele (p=0.104) that can be seen in Figure 7.  To better understand the trend in the change of 
ADHD over time a secondary analysis indicated significantly higher total ADHD symptom severity for 
children with at least one NT-3 risk allele compared to children with no risk NT-3 allele at the final time 
point [t(114)=-3.270, p<0.01], but this difference was not evident at baseline.  There was significant 
variation around the average intercept (χ2=1103.96, df=143, p<0.001) and the average slope (χ2=361.32, 
df=143, p<0.001) that was not accounted for by the model.   
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TABLE 9: Association of NT-3 risk allele with Total ADHD symptom severity over time 
Results             Analysis    
Fixed Effects    Coefficient  SE  T ratio  p 
Level 1 intercept 
   Intercept    16.57   1.17  14.22            <0.001 
   NT-3         1.45   1.97    0.74              0.462 
Level 1 linear slope 
   Intercept    -0.22   0.13  -1.64             0.102 
   NT-3        0.34   0.21   1.64             0.104 
 
Random Effects   Variance Component      df  χ2      p 
  Level 1 intercept   10.61   143  1103.96 <0.001 
  Level 1 linear slope     0.97   143    361.32 <0.001  
 
Figure 7: Association of NT-3 risk allele with Total ADHD symptom severity over time 
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Figure 7: The model is centered at the baseline age, 3-4 years, which is indicated as age 0 on the x-axis.  
The y-axis indicates total ADHD Symptom Severity.  Red line indicates at least one risk allele for NT-3, 
while the blue is no risk alleles for NT-3.  
Association of NT-3 risk allele with Inattentive symptom severity over time 
 As shown in Table 10 and depicted in Figure 8, the estimated mean of Inattentive symptom 
severity at age 3-4 years in children without the NT-3 risk allele was 7.11 (SE=0.57) with a nonsignificant 
increase of 0.36 (SE=0.95) in children with at least one NT-3 risk allele (p=0.703) and the average slope 
or rate of change in Inattentive symptom severity did not differ by NT-3 risk allele from age 3-4 years to 
age 11 years (p=0.297). There was significant variation around the average intercept (χ2=726.01, df=143, 
p<0.001) and the average slope (χ2=334.96, df=143, p<0.001) that was not accounted for by the model.  
TABLE 10: Association of NT-3 risk allele with Inattentive symptom severity over time 
Results             Analysis    
Fixed Effects    Coefficient  SE  T ratio  p 
Level 1 intercept 
   Intercept    7.11   0.57  12.38              <0.001 
   NT- 3        0.36   0.95    0.38               0.703 
Level 1 linear slope 
   Intercept     0.24   0.08  3.12              <0.01 
   NT-3        0.13   0.12   1.05              0.297 
 
Random Effects   Variance Component      df  χ2      p 
  Level 1 intercept   24.64   143  726.01   <0.001 
  Level 1 linear slope     0.54   143   334.96  <0.001  
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Figure 8: Association of NT-3 risk allele with Inattentive symptom severity over time 
 
Figure 8: The model is centered at the baseline age 3-4 years, which is indicated as age 0 on the x-axis.  
The y-axis indicates total Inattentive Symptom Severity.  Red line indicates at least one risk allele for NT-
3, while the blue is no risk alleles for NT-3.  
Association of NT-3 risk allele with Hyperactive/Impulsive symptom severity over time 
 As shown in Table 11 and depicted in Figure 9, the estimated mean of Hyperactive/Impulsive 
symptom severity at age 3-4 years in children without the NT-3 risk allele was 9.44 (SE=0.65).  There was 
a small non-significant increase of 1.07 (SE=1.12) in children with at least one NT-3 risk allele (p=0.342).  
The average slope or rate of change in Hyperactive/Impulsive symptom severity did not differ by NT-3 
risk allele from age 3-4 years to age 11 years.  However, there was a trend for rate of change as a 
function of NT-3 allele (p=0.063) that can be seen in Figure 9.  To better understand the trend in the 
change of ADHD over time a secondary analysis indicated significantly higher total 
Hyperactive/Impulsive symptom severity for children with at least one NT-3 risk allele compared to 
children with no risk NT-3 allele at the final time point [t(114)=-3.865, p<0.01].  This difference was not 
significant at baseline. There was significant variation around the average intercept (χ2=1159.49, df=143, 
p<0.001) and the average slope (χ2=382.78, df=143, p<0.001) that was not accounted for by the model.  
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TABLE 11: Association of NT-3 risk allele with Hyperactive/Impulsive symptom severity over time 
Results             Analysis    
Fixed Effects    Coefficient  SE  T ratio  p 
Level  
   Intercept    9.44   0.65  14.418            <0.001 
   NT-3        1.07   1.12    0.95              0.342 
Level 1 linear slope 
   Intercept     -0.46   0.08  -5.80            <0.01 
   NT-3        0.21   0.12   1.88             0.063 
 
Random Effects   Variance Component      df  χ2      p 
  Level 1 intercept    6.03   143              1159.49  <0.001 
  Level 1 linear slope     0.56   143   382.78  <0.001  
 
Figure 9: Association of NT-3 risk allele in Hyperactive/Impulsive symptom severity over time 
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Figure 9: The model is centered at the baseline age, 3-4 years, which is indicated as age 0 on the x-axis.  
The y-axis indicates total Hyperactive/Impulsive Symptom Severity.  Red line indicates at least one risk 
allele for NT-3, while the blue is no risk alleles for NT-3.  
Brain-derived Neurotrophic Factor (BDNF) 
Association of BDNF risk allele with Total ADHD symptom severity over time 
 As shown in Table 12 and depicted in Figure 10, the estimated mean of Total ADHD symptom 
severity at age 3-4 years in children without the BDNF risk allele was 11.36 (SE=2.58) with a significant 
increase of 6.42 (SE=2.76) in children with at least one BDNF risk allele (p=0.021).  The average slope or 
rate of change in Total ADHD symptom severity did not differ by BDNF risk allele from age 3-4 years to 
age 11 years (p=0.418).  There was significant variation around the average intercept (χ2=1071.85, 
df=143, p<0.001) and the average slope (χ2= 370.21, df=143, p<0.001) that was not accounted for by the 
model.  
TABLE 12: Association of BDNF risk allele with Total ADHD symptom severity over time 
Results             Analysis    
Fixed Effects    Coefficient  SE  T ratio  p 
Level 1 intercept 
  Intercept    11.36   2.58    4.41  <0.001 
  BDNF       6.42   2.76    2.33  0.021 
Level 1 linear slope 
  Intercept     0.18   0.38   0.49  0.626 
  BDNF      -0.32   0.39  -0.81  0.418 
 
Random Effects   Variance Component      df  χ2      p 
  Level 1 intercept            109.09   143  1071.85 <0.001 
  Level 1 linear slope   0.99   143    370.21 <0.001  
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FIGURE 10: Association of BDNF risk allele with Total ADHD symptom severity over time 
 
Figure 10: The model is centered at the baseline age, 3-4 years, which is indicated as age 0 on the x-axis.  
The y-axis indicates Total ADHD Symptom Severity.  Red line indicates at least one risk allele for BDNF, 
while the blue is no risk alleles for BDNF.  
Association of BDNF risk allele with Inattentive symptom severity over time 
 As shown in Table 13 and depicted in Figure 11, the estimated mean of Inattentive symptom 
severity at age 3-4 years in children without the BDNF risk allele was 4.83 (SE=1.25) with a significant 
increase of 2.72(SE=1.34) in children with at least one BDNF risk allele (p=0.044).  The average slope or 
rate of change in Inattentive symptom severity did not differ by BDNF risk allele from age 3-4 years to 
age 11 years (p=0.782).  There was significant variation around the average intercept (χ2=706.97, 
df=143, p<0.001) and the average slope (χ2= 339.50, df=143, p<0.001) that was not accounted for by the 
model.  
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TABLE 13: Association of BDNF risk allele with ADHD Inattentive symptom severity over time 
Results             Analysis    
Fixed Effects    Coefficient  SE  T ratio  p 
Level 1 intercept 
  Intercept    4.82   1.25    3.87  <0.001 
  BDNF       2.72   1.34    2.03  <0.05 
Level 1 linear slope 
  Intercept     0.34   0.21   1.61  0.110 
  BDNF      -0.06   0.21  -0.28  0.782 
Random Effects   Variance Component      df  χ2      p 
  Level 1 intercept              23.95   143  706.97  <0.001 
  Level 1 linear slope   0.30   143   339.50  <0.001  
 
FIGURE 11: Association of BDNF risk allele with Inattentive symptom severity over time 
 
Figure 11: The model is centered at the baseline age, 3-4 years, which is indicated as age 0 on the x-axis.  
The y-axis indicates total Inattentive Symptom Severity.  Red line indicates at least one risk allele for 
BDNF, while the blue is no risk alleles for BDNF.  
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Association of BDNF risk allele with Hyperactive/Impulsive symptom severity over time 
 As shown in Table 14 and depicted in Figure 12, the estimated mean of Hyperactive/Impulsive 
symptom severity at age 3-4 years in children without the presence of the BDNF risk allele was 6.53 
(SE=1.40) with a significant increase of 3.69 (SE=2.44) in children with the presence of at least one BDNF 
risk allele (p=0.016).  The average slope or rate of change in Hyperactive/Impulsive symptom severity did 
not differ by BDNF risk allele from age 3-4 years to age 11 years (p=0.417).  There was significant 
variation around the average intercept (χ2=1128.72, df=143, p<0.001) and the average slope (χ2= 390.73, 
df=143, p<0.001) that was not accounted for by the model.  
TABLE 14: Association of BDNF risk allele with in Hyperactive/ Impulsive severity over time 
Results             Analysis    
Fixed Effects    Coefficient  SE  T ratio  p 
Level 1 intercept 
  Intercept    6.53   1.40    4.65  <0.001 
  BDNF       3.69   1.52    2.44  0.016 
Level 1 linear slope 
  Intercept    -0.16   0.19   -0.82  0.417 
  BDNF      -0.25   0.20   -1.26  0.210 
Random Effects   Variance Component      df  χ2      p 
  Level 1 intercept              35.28   143              1128.72  <0.001 
  Level 1 linear slope   0.32   143   390.73  <0.001  
 
 
 
 
 
NEURODEVELOPMENTAL GENES ADHD     48 
FIGURE 12: Association of BDNF risk allele with in Hyperactive/ Impulsive symptom severity over time 
 
Figure 12: The model is centered at the baseline age, 3-4 years, which is indicated as age 0 on the x-axis.  
The y-axis indicates total Hyperactive/Impulsive Symptom Severity.  Red line indicates at least one risk 
allele for BDNF, while the blue is no risk alleles for BDNF.  
Regulator of G protein signaling 4 (RSG4)   
Association of RGS4 risk allele with Total ADHD symptom severity over time 
 As shown in Table 15 and depicted in Figure 13, the estimated mean of Total ADHD symptom 
severity at age 3-4 years in children without the RGS4 risk allele was 15.61 (SE=1.58), with an increase of 
2.39 (SE=1.96) with at least one RGS4 risk allele (p=0.223).  The average slope or rate of change in Total 
ADHD symptom severity did not differ by RGS4 risk allele from age 3-4 years to age 11 years (p=0.378).  
There was significant variation around the average intercept (χ2=1101.34, df=143, p<0.001) and the 
average slope (χ2= 368.43, df=143, p<0.001) that was not accounted for by the model.   
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TABLE 15: Association of RGS4 risk allele with Total ADHD symptom severity  
Results             Analysis    
Fixed Effects    Coefficient  SE  T ratio       p 
Level 1 intercept 
  Intercept    15.61   1.58   9.91  <0.001 
  RGS4       2.39   1.95   1.22  0.223 
Level 1 linear slope 
  Intercept      0.02   0.17   0.09   0.926 
  RGS4       -0.19   0.22  -0.89    0.378 
 
Random Effects   Variance Component      df  χ2      p 
  Level 1 intercept              111.91   143  1101.34 <0.001 
  Level 1 linear slope     0.97   143    368.43 <0.001 
 
FIGURE 13: Association of RGS4 risk allele with Total ADHD symptom severity over time 
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Figure 13: The model is centered at the baseline age, 3-4 years, which is indicated as age 0 on the x-axis.  
The y-axis indicates Total ADHD Symptom Severity.  Red line indicates at least one risk allele for RGS4, 
while the blue is no risk alleles for RGS4.  
Association of RGS4 risk allele with Inattentive symptom severity over time 
 As shown in Table 16 and depicted in Figure 14, the estimated mean Inattentive symptom 
severity at age 3-4 years in children without the RGS4 risk allele was 6.71 (SE=0.73), with a 
nonsignificant increase of 0.87 (SE=0.94) with the least one RGS4 risk allele (p=0.354).  The average 
slope or rate of change in Inattentive symptom severity did not differ by RGS4 risk allele from age 3-4 
years to age 11 years (p=0.330).  There was significant variation around the average intercept 
(χ2=724.61, df=143, p<0.001) and the average slope (χ2= 336.94, df=143, p<0.001) that was not 
accounted for by the model. 
TABLE 16: Association of RGS4 risk allele with change in Inattentive symptom severity over time 
Results             Analysis    
Fixed Effects    Coefficient  SE  T ratio  p 
Level 1 intercept 
  Intercept    6.71   0.73   9.17  <0.001 
  RGS4      0.87   0.94  0.93    0.354 
Level 1 linear slope 
  Intercept      0.35   0.09  3.945   <0.001 
  RGS4       -0.12   0.12  -0.98      0.330 
 
Random Effects   Variance Component      df  χ2      p 
  Level 1 intercept              25.54   143  724.61  <0.001 
  Level 1 linear slope                0.30   143   336.94  <0.001 
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FIGURE 14: Association of RGS4 risk allele with Inattentive symptom severity over time 
 
Figure 14: The model is centered at the baseline age, 3-4 years, which is indicated as age 0 on the x-axis.  
The y-axis indicates total Inattentive Symptom Severity.  Red line indicates at least one risk allele for 
RGS4, while the blue is no risk alleles for RGS4.  
Association of RGS4 risk allele with Hyperactive/Impulsive symptom severity over time 
 As shown in Table 17 and depicted in Figure 15, the estimated mean of Hyperactive/Impulsive 
symptom severity at age 3-4 years in children without the RGS4 risk allele was 8.87 (SE=0.91), with an 
increase of 1.55 (SE=1.12) with at least one RGS4 risk allele (p=0.166).  The average slope or rate of 
change in Hyperactive/ Impulsive symptom severity did not differ by RGS4 risk allele from age 3-4 years 
to age 11 years (p=0.533).  There was significant variation around the average intercept (χ2=1156.25, 
df=143, p<0.001) and the average slope (χ2= 392.51, df=143, p<0.001) that was not accounted for by the 
model. 
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TABLE 17: Association of RGS4 risk allele with Hyperactive/ Impulsive symptom severity over time 
Results             Analysis    
Fixed Effects    Coefficient  SE  T ratio       p 
Level 1 intercept 
  Intercept    8.87   0.91   9.73  <0.001 
  RGS4      1.55   1.12   1.39    0.166 
Level 1 linear slope 
  Intercept    -0.33   0.10  -3.263   <0.001 
  RGS4      -0.08   0.12  -0.62      0.533 
 
Random Effects   Variance Component      df  χ2      p 
  Level 1 intercept              36.05   143              1156.25  <0.001 
  Level 1 linear slope                0.57   143   392.51     <0.001 
 
FIGURE 15: Association of RGS4 risk allele with Hyperactive/ Impulsive symptom severity over time 
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Figure 15: The model is centered at the baseline age, 3-4 years, which is indicated as age 0 on the x-axis.  
The y-axis indicates total Hyperactive/Impulsive Symptom Severity.  Red line indicates at least one risk 
allele for RGS4, while the blue is no risk alleles for RGS4.  
Total Risk Genes 
Three out of the four genes showed some evidence of gene effects with NRG-1 and BDNF, 
having significant associations with Total ADHD symptoms severity, and NT-3 showing marginal evidence 
of a trend toward allele-related differences.  To assess the additive role of the risk alleles for the 
association with Total ADHD symptom severity, the number of risk alleles for the three genes were 
summed to arrive at a sum gene risk variable (possible range 0 -6).  Due to low frequencies for risk 
values 0 (n=3) and 6 (n=2), those with 0 and 1 risk alleles were combined as were those with 5 and 6 risk 
alleles.  Table 18 shows the frequency distribution for sum number of risk alleles. 
TABLE 18: Distribution of Sum Number of Risk Alleles  
Sum Number 
of Risk Alleles        N 
 
 0-1  16 
 2  23 
 3  41 
 4  44 
 5-6  21 
Note: The 0-1 group is comprised of 3 children with 0 risk alleles and 13 with 1 risk allele.  The 5-6 group 
is comprised of 19 and 2 children with 5 and 6 risk alleles, respectively. 
To determine the association between the sum of risk alleles and Total ADHD, Inattentive and 
Hyperactive/ Impulsive symptom severity Pearson correlations revealed significant positive associations 
between symptom severity and total number of risk alleles at each time-point (T1-T8) with increasing r 
values as children got older (Figure 16).  Figures 16 A-H show symptom levels as a function of number of 
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risk alleles at each annual time point.  Notably, by the latter time points (T7 and T8) there is a clear 
linear relation between number of risk alleles and ADHD symptom severity.  
FIGURE 16: Correlation of Number of Risk Alleles with Total ADHD symptoms, Inattentive symptoms and 
Hyperactive/Impulsive Symptoms at annual time points.   
 
* = all three p<0.01, **= all three p<0.001 
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Figure 17: Total ADHD symptoms as a function of number of risk alleles over time  
A.  Time 1       B.  Time 2 
                 
C.  Time 3       D. Time 4 
           
E.  Time 5      F.  Time 6 
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G.  Time 7      H.  Time 8                        
                   
 
Gene x Environment Interaction 
To determine whether environmental risk factors for ADHD interacted with gene effects, the 
following risk factors were examined using exploratory moderation analyses: maternal gestational 
diabetes, maternal substance use (alcohol, tobacco, illicit drug use) during pregnancy and low SES (SES 
less than the 10%ile for SES for the sample).  Table 19 displays the frequencies for the environmental 
risk factors.  The following are the only significant results that were obtained in this exploratory analysis.  
TABLE 19: Distribution of Sum Number of Environmental risk alleles. 
Prenatal Risk Factor  No   Yes 
Maternal Gestational   130  15   
Diabetes    
 
Maternal Tobacco Use  119  26 
 
Maternal Alcohol Use  113  32 
 
Maternal Illicit Drug Use 135  10 
   
Low SES (<10%)   133  12 
 
Any Prenatal Risk Factor 80  65 
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NRG-1 and Early Environmental Risk Factor of Maternal gestational diabetes 
Maternal gestational diabetes was examined as a moderator of the relation between NRG-1 and 
Total ADHD symptom severity at Time 1.  NRG-1 risk alleles and presence of maternal gestational 
diabetes were entered in the first step of the regression analysis.  In the second step of the regression 
analysis, the interaction term between NRG-1 risk alleles and maternal gestational diabetes was 
entered, and it explained a significant increase in Total ADHD symptom severity [ΔR2 = 0.084, 
F(3,141)=4.314, p<0.01].  Maternal gestational diabetes was a significant moderator of the relationship 
between NRG-1 and Total ADHD symptom severity, such that having at least one NRG-1 risk allele and 
maternal gestational diabetes increases Total ADHD Symptom severity compared to maternal 
gestational diabetes without a NRG-1 risk allele; however, Total ADHD symptom severity was lower 
without maternal gestational diabetes and at least one risk allele for NRG-1 compared to both maternal 
gestational diabetes risk allele and NRG-1 allele risk and no maternal gestational diabetes and no NRG-1 
risk allele (See Figure 18).   
Figure 18: Moderation of NRG-1 and Maternal Gestational Diabetes.  
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NRG-1 and Early Environmental Risk Factor of Maternal Alcohol Use 
Maternal alcohol use during pregnancy was examined as a moderator of the relation between 
NRG-1 and Total ADHD symptom severity at Time 1.  NRG-1 risk alleles and presence of maternal alcohol 
use were entered in the first step of the regression analysis.  In the second step of the regression 
analysis, the interaction term between NRG-1 risk alleles and maternal alcohol use was entered, and it 
explained a significant increase in Total ADHD symptom severity [ΔR2 = 0.087, F(3,141)=4.497, p<0.01].  
Maternal alcohol use was a significant moderator of the relationship between NRG-1 and Total ADHD 
symptom severity, such that having no NRG-1 risk allele and no maternal alcohol use had lowest Total 
ADHD severity compared to maternal alcohol use with and without the NRG-1 risk allele and maternal 
alcohol use and at least one NRG-1 risk factor (See Figure 19).  
Figure 19: Moderation of NRG-1 and Maternal Alcohol Use.  
 
 
 
 
 
 
 
 
 
 
NTF3 and Early Environmental Risk Factor of Maternal Tobacco Use 
Maternal tobacco use during pregnancy was examined as a moderator of the relation between 
NTF3 and Total ADHD symptom severity at Time 1.  NTF3 risk alleles and presence of maternal tobacco 
use were entered in the first step of the regression analysis.  In the second step of the regression 
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analysis, the interaction term between NTF3 risk alleles and maternal tobacco use was entered, and it 
explained a significant increase in Total ADHD symptom severity [ΔR2 = 0.08, F(3,141)=3.852, p<0.05].  
Maternal tobacco use was a significant moderator of the relationship between NTF3 and Total ADHD 
symptom severity, such that having at no NTF3 risk alleles and no maternal tobacco use resulted in the 
lower Total ADHD severity compared to maternal tobacco use and no NTF3; however, having at least 
one NTF3 risk allele and maternal tobacco use was lower compared to no maternal tobacco use and at 
least one NTF3 risk allele (See Figure 20).  
Figure 20: Moderation of NTF3 and Maternal Tobacco Use.  
 
 
BDNF and Early Environmental Risk Factor of Maternal Gestational Diabetes 
Maternal gestational diabetes during pregnancy was examined as a moderator of the relation 
between BDNF and Total ADHD symptom severity at Time 1.  BDNF risk alleles and presence of maternal 
gestational diabetes were entered in the first step of the regression analysis.  In the second step of the 
regression analysis, the interaction term between BDNF risk alleles and maternal gestational diabetes 
was entered, and it explained a significant increase in Total ADHD symptom severity [ΔR2 = 0.06, 
F(3,141)=3.060, p<0.05].  Maternal gestational diabetes was a significant moderator of the relationship 
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between BDNF and Total ADHD symptom severity, such that having no BDNF risk alleles and no 
maternal tobacco use resulted in the high Total ADHD severity compared to maternal gestational 
diabetes and no BDNF risk alleles; however, having at least one BDNF risk allele and maternal 
gestational diabetes was higher compared to no maternal tobacco use and at least one BDNF risk allele.  
(See Figure 21).  
Figure 21: Moderation of BDNF and Maternal Gestational Diabetes.  
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with weak and inconsistent results (Kustanovich, et al., 2003; Mill et al., 2005; Loo et al., 2003; Ribasés 
et al., 2012; Faraone et al., 2005; Gizer, Ficks, & Waldman, 2009).  Similarly, serotonin system genes 
necessitate further investigation.  Beyond genes affecting neurotransmitter systems associated with 
ADHD, genes involved in brain growth and development have indicated that some promising areas that 
also suggest greater investigation (Mill et al., 2002; Mill et al., 2004; Mick & Faraone, 2008; Hawi et al., 
2013b).  Findings from genome-wide association studies have not yet yielded definitive results in 
identifying a gene or genes responsible for ADHD (Neale et al., 2010; Hinney et al., 2011; Ebejer et al., 
2013).  Theoretically BDNF and glutamate-related genes suggest an association with ADHD, however, 
again, findings have been mixed (Turic et al., 2004; Kent et at., 2005). 
In response to the limited success of previous research to identify specific genes related to the 
presence of ADHD, the current study undertook a novel neurodevelopmental approach in an attempt to 
elucidate the genetic basis of ADHD.  The study followed a longitudinal sample of preschool-age children 
that was evaluated for the presence of ADHD symptoms annually for 8 years.  Four genes involved in 
neurodevelopment were selected for this exploratory study; NRG-1, NT-3, BDNF, RGS4.  Additionally, 
information on early environmental risk factors (i.e., maternal gestational diabetes, maternal substance 
use - alcohol, tobacco, illicit substance-) was collected to explore moderating relations between genetic 
risk and early environmental risk. 
The initial modeling of ADHD symptoms over time, independent of other factors, revealed little 
group-level change in total ADHD symptom severity with age.  However, there was significant individual 
variability at the initial preschool age time-point as well as in change in severity over time.  In contrast to 
total symptom levels, there was a significant increase in inattentive symptom severity with increasing 
age and a significant decrease in hyperactive/impulsive symptoms over time.  Nevertheless, again, there 
was significant inter-individual variability in both the initial level and the slope of change over time in 
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both symptom domains.  These results were largely expected as the typical course of ADHD is such that 
the high prevalence of ADHD symptoms in early childhood tends to decrease through adolescence and 
adulthood (Campbell, 1995; Connor, 2002, Halperin, Trampush, Miller, & Newcorn, 2008, Faraone, 
Biederman, & Mick, 2006). Symptoms of hyperactivity/impulsivity decrease over time, while symptoms 
of inattention are more likely to persist (Biederman, Mick, & Faraone, 2000; DuPaul & Stoner, 2004; 
Wolraich et al., 2005).  
Among the four genes that were evaluated, three were found to have a notable association with 
ADHD symptomatology.  Individuals with at least one risk allele of NRG-1 or BDNF had more total ADHD, 
inattentive, and hyperactive/impulsive symptoms at preschool age, although the rate of change in 
symptom severity over time did not vary as a function of NRG-1 or BDNF genotype.  These findings are 
consistent with the hypothesis that NRG-1 and BDNF influence the onset of ADHD, but not the trajectory 
of ADHD over development from the preschool to school-age years.  NRG-1 is associated with fine-
tuning of cortical circuitry and synaptic efficacy, and has an influence on the transcription of multiple 
classes of neurotransmitter receptors.  These changes in neuronal formation have been associated with 
behavioral outcomes (Arnsten, 2006; Yin et al., 2013).  BDNF is involved in neurodevelopment, synapse 
regulation and synaptic plasticity, modulates synaptic transmission, and is associated with behavioral 
disorders, such mood disorders and schizophrenia (Fernandes et al., 2014).  BDNF also demonstrates a 
protective role with neuronal homeostasis and is protective against neuronal insults.  Both are 
associated with synaptic plasticity and long-term functionality.  Changes in neurotropic activity during 
brain development can results in neuronal dysfunction which can lead to disordered behavior.  It was 
hypothesized that both NRG-1 and BDNF would be associated with ADHD symptoms at preschool and 
associated with the persistence of ADHD symptoms until school age.  Our results supported the onset of 
ADHD symptoms being associated with NRG-1 and BDNF, but not the persistence of ADHD, at least prior 
to puberty. 
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In contrast, NT-3 genotype did not significantly relate to ADHD onset or trajectory.  However, a 
trend emerged suggesting that NT-3 might influence the trajectory of total ADHD symptoms and 
hyperactive/impulsive symptoms in particular.  Although NT-3 has been identified as regulating CNS 
neurogenesis during early development, results suggest that NT-3 may impact ADHD symptoms later in 
development.  Finally, RGS4 risk alleles did not impact ADHD onset or trajectory.  Although, we 
hypothesized that RGS4 allelic variability would relate to ADHD symptoms onset and trajectory, out of 
the four genes evaluated it was the one with the least substantial theoretical support. 
Collectively this information suggests a role for three of the neurodevelopmental genes 
examined, with their effects primarily on the onset of ADHD symptoms.  Although, this was an 
exploratory study, it was hypothesized that these genes would have an impact on the trajectory of 
ADHD.  Apart from, NT-3, which showed a trend such that it impacted ADHD later in development, the 
other two genes only related to early onset at preschool age.  One possible explanation is that these 
neurodevelopmental genes have their largest impact on the early onset ADHD symptoms and other 
genes have greater contribution to influencing ADHD symptoms in late school age (Pingault et al., 2015).  
Alternatively, individuals with NT-3 risk allele are more likely to grow into their genes in late school age 
and early adolescence. 
Although the results indicated an association such that individual genes related to ADHD 
symptomatology, it is highly likely that ADHD is not a result of a few genes, but rather a collection of 
genes with small effect size that contribute to the onset and/or the persistence of the disorder.  To 
examine the collective nature of multiple genetic risks, the next analysis combined total number of 
genetic risk alleles.  It was expected that with more genetic risk one would be more likely to have an 
increase in ADHD symptoms (Rutter, 1987).  As proposed, the number of genetic risk alleles was 
associated with increased total ADHD, inattentive, and hyperactive/ impulsive symptoms at each time 
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point, such that the more risk alleles an individual had the more ADHD symptoms.  Notably, the strength 
of the association between number of risk alleles and ADHD symptoms increased with increasing age.  
This suggests an additive effect of genetic risk on ADHD symptoms at onset and over time, and raise the 
possibility that as children get older, genetic influences on ADHD severity get stronger as environmental 
influences diminish.  Although the combination of risk alleles from the three genes assessed was 
associated with ADHD, it is very likely that many more genes, not only the ones selected for this study, 
are involved as there continues to be significant unaccounted variability.  
Exploratory Moderation Analyses 
Exploratory analyses into early environmental factors were conducted to evaluate gene-by-
environment interactions and to explore the unaccounted-for variability.  The influence of maternal 
gestational diabetes and maternal substance use during pregnancy was mixed.  It was hypothesized that 
early environmental risk factors would moderate ADHD symptoms and provide further explanation for 
individual variability in symptomatology.  Only a few of several analyses conducted yielded significant 
findings, and some are difficult to interpret. 
Significant moderation was found between NRG-1 and two maternal risk factors; gestational 
diabetes and maternal alcohol use during pregnancy.  Yet, the pattern of the interaction differed 
between these two environmental risk factors.  Maternal gestational diabetes was unrelated to ADHD 
symptom severity in those without an NRG-1 risk allele.  However, among individuals with an NRG-1 risk 
allele, those with and without maternal gestational diabetes had the highest and lowest levels of ADHD 
symptoms, respectively.  As stated above, the nature of the interaction was different for maternal 
alcohol use during pregnancy.  Children of mothers who drank alcohol during pregnancy had elevated 
levels of ADHD symptoms irrespective of NRG-1 risk, as did those with an NRG-1 risk allele irrespective 
of maternal alcohol use.  Those without the genetic (i.e., NRG-1 risk allele) and environmental (i.e., 
NEURODEVELOPMENTAL GENES ADHD     65 
maternal alcohol use during pregnancy) risk factors had significantly lower levels of ADHD symptoms as 
compared to the other three groups.  Thus, it appears that effect of gestational diabetes on the 
offspring’s neurodevelopment is dependent upon NRG-1 risk status.  In contrast, maternal alcohol use 
during pregnancy has negative effects irrespective of genetic status.   
A significant interaction also emerged between NT-3 risk status and maternal tobacco use 
during pregnancy, although the nature of the interaction was surprising and interpretation of this 
finding is less clear.  NT-3 risk and maternal tobacco use resulted in lower levels of ADHD symptoms 
compared to those with the genetic risk but no maternal tobacco use.  Overall, the nature of this 
interaction suggests that NT-3 risk is reduced in those whose mothers smoked during pregnancy. 
Finally, significant moderation was found between BDNF and maternal gestational diabetes.  
Here the nature of the interaction was such that BDNF risk had a minimal impact when gestational 
diabetes was not present.  However, among those with gestational diabetes, elevated ADHD symptom 
levels were seen only in those children who had a BDNF risk allele. 
Taken together it appears that maternal gestations diabetes is associated with elevated levels of 
ADHD symptoms only in youth at elevated genetic risk (via NRG-1 and/or BDNF), consistent with a gene-
by-environment interaction.  In contrast, maternal alcohol use during pregnancy may moderate the 
influence of NRG-1 on ADHD symptoms.  Although the environmental risk analysis was exploratory, it 
was expected that environmental risk factors would moderate genetic risk.  In contrast, the interaction 
involving NT-3 and maternal tobacco use is more difficult to explain and understand.  It appears that 
maternal smoking may mitigate the risk associated with NT-3.  While the results for the impact of 
environmental factors are mixed, these analyses are exploratory and may reflect chance findings given 
the large number of analyses conducted.  Even though the analyses are exploratory and limited these 
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areas of investigation could yield valuable information in understanding the impact of suboptimal early 
prenatal development brain.    
Limitations  
  As this was a small pilot study there were several limitations.  The most apparent limitation is 
the small sample size.  As stated previously, the current sample was selected from a slightly larger 
longitudinal study.  Compared to contemporary genetic studies the sample size is substantially smaller.  
However, despite the small sample size, there were some significant findings with three out of the four 
genes studied.  Although this does not exclude the chance of random findings, it does suggest that a 
potential avenue of further research.  Environmental risk factors information was collected at the initial 
evaluation time point, but was still dependent on retrospective recall.  Further, the information that was 
used in the analysis was binary (i.e., endorsement or lack of endorsement).  Greater sensitivity might 
have emerged had dimensional measures of environmental risk been employed.  Additionally, the 
binary nature could lead to uncaptured variability between individuals.  For example, there could be a 
difference in outcome depending on the prenatal developmental time point the substance was used, or 
the frequency and extent of the substance that was used.  With maternal gestational diabetes, there 
could be variability in management of the disease and ultimately variability on the impact on the 
developing fetus and in turn impacting neurological development.  Additionally, the low frequency of 
endorsement of maternal substance use limited the use of some of the analysis.  A sample with greater 
proportion of maternal substance use including more detailed information on the timing of exposure 
during pregnancy, and the impact of varying amounts of fetal exposure, would allow more depth of 
analysis such as time sensitivity and dose dependent moderation.  Finally, it is possible that respondents 
were not completely forthcoming with information, particularly as related to more sensitive topics such 
as substance use during pregnancy.   
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Despite clear evidence from behavioral genetic studies for the importance of genes in the 
etiology of ADHD, the elucidation of specific genes has not been as fruitful or rewarding as expected.  
Much of the field has moved in the direction of genome-wide analyses, and some genetic markers are 
beginning to emerge (Franke et al., 2012; Elia et al., 2012; Sánchez-Mora et al., 2015).  However, such 
analyses require extremely large samples and are generally not helpful for identifying gene-by-
environment interactions because it is difficult, if not impossible to acquire individualized environmental 
data from such large samples (Moore, 2017).  This study offers a somewhat different approach to 
studying and understanding the etiology of this neurodevelopmental disorder by focusing on genes 
involved in neurodevelopment. 
The current study was limited in both the breadth and depth of possible genes involved in the 
onset and the persistence of ADHD.  There are many more genes that are involved in 
neurodevelopmental processes that affect aspects of neural development, which impact neural 
pathways, and ultimately influence behavior that suggest additional avenues of investigation.  Even 
among the genes evaluated, only single nucleotide polymorphisms were evaluated and yet there are 
possible alternative gene variants even in the genes evaluated that can impact ADHD symptomatology.  
One clear area of further research is to explore the cumulative nature of neurodevelopmental risk 
alleles of additional neurodevelopmental genes.  Another area to explore is the impact of these genes 
on ADHD symptoms in later adolescence and early adulthood, where genes involved in the maturation 
of the cortex exert the most impact and can differentiate those that continue to experience functionally 
impactful symptoms of ADHD.  Further, the current study did not have the power to properly evaluate 
the impact on males versus females.  Finally, and possibly most importantly, due to the exploratory 
nature of the study, these findings need to be replicated.  Genetic findings, especially with a limited 
sample require further analyses. 
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Future Directions 
Additional routes of further research can include environmental factors.  The current study 
looked at the prenatal environmental risk factors to identify additional areas that can impact individual 
symptomatology of ADHD.  Maternal alcohol use, tobacco use and maternal gestational diabetes were 
identified as possible factors.  In addition to these factors, physical abuse, child neglect, maternal 
exposure to stress, trauma, poor nutrition, premature birth, perinatal complications, very low birth 
weight, early hypoxic episodes, and exposure to environmental toxins can also be explored as risks to 
early neurologic development.  Early environmental factors can also have a role in the expression of 
these genes.  Further exploration of gene production will provide better understand of gene and 
environmental interactions.  More accurate measurement and assessment of environmental factors can 
contribute to the understanding of cumulative risk on neurodevelopment.  
With the understanding that the developmental trajectory of ADHD varies in presentation and 
persistence over development; better understanding of the factors that impact ADHD symptomatology 
can give direction to those treating individuals with the disorder in a more personalized way.  It is 
possible that in the future genetic profiles could identify individuals at risk for the disorder prior to 
preschool age and provide information on the possible severity and persistence over development.  This 
information can be used to structure early optimal behavioral treatment and symptom management.  
Genetic profiles may also suggest optimal pharmacological interventions.   
Conclusions 
The findings of this study suggest a possible fruitful new direction into both the understanding 
of the etiology of ADHD across development and an alternative approach into exploring 
neurodevelopmental genetic risk factors.  Going forward this study suggests an approach that considers 
the onset and persistence of ADHD symptoms and identifies those genes that undermine optimal 
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neurodevelopment.  Lastly, the study also suggests incorporating early environmental factors that can 
negatively impact brain development and how these factors, in coordination with genetic factors, 
manifest in psychopathology.  Although the current study focused on ADHD symptomatology, 
investigations into other neurodevelopmental disorders, such as Autism Spectrum Disorder, may also 
benefit from this approach.  
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Appendix 
Table 1: Summary of genetic results 
 
Gene Type of Study Results 
DRD4 Case control 
 
7 –repeat – inconsistent findings, no single significant findings 
 
Case control 
Meta-analysis 
7 –repeat - OR = 1.9 (p < 0.001) 
Family-based 
Meta-analysis 
7 –repeat - OR = 1.4 (p = 0.02) 
Case control 
 
2 and 4-repeat allele – not significant 
DRD5 Case control 
 
148-bp allele – association 
136-bp and 146-bp alleles – no association 
Family based 148-bp allele – association 
136-bp and 146-bp alleles – no association 
Meta-analysis 2/4 studies found 148-bp allele – association 
 
DRD2 Case control 
 
A1 allele – inconsistent association 
A2 allele – association with hyperactivity and impulsvity 
DRD1 Case control association with DRD1 in childhood combined type ADHD, but 
not in adulthood ADHD 
two SNPs associated with ADHD (rs4532, rs265981) 
DAT1 Case control No association with ADHD 
DBH Case control A1 and A2 allele – significant but weak association 
TH Case control No association 
DRD3 Case control No association 
COMT Case control Inconsistent association (Val108Met polymorphism) 
MAO-A Case control 30-bp tandem repeat of the promoter region of the gene in two 
ethnic populations 
SLC6A2/NET1 Case control 
Meta-analysis 
SNP studies 
Association 
No association 
rs3785157 – association in two studies, not replicated 
rs998424 – association in one study, not replicated 
rs3785143 and rs11568324 – association in one study 
ADRA1A Case control 
Meta-analysis 
Association 
No association 
ADRA1B Case control 
Meta-analysis 
Association 
No association 
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SLC6A2/NET1 
and ADRA1B 
Case control 
 
multi SNP haplotypes association 
ADRA2A Case control 
 
G-1291C allele at the promoter region, not replicated 
G-1291C association with inattentive subtype 
Serotonin 
Receptor Genes 
Case control study 
 
 
HTR1B receptor G861C allele with ADHD – association, not 
replicated 
HTR2B receptor T102C and G1438A – not associated 
HTR1E receptor – no association 
HTR3B receptor – no association 
Family based Association with His452Tyr allele and not the T102C allele, not 
replicated 
Serotonin 
transporter 
Case control  5-HTTLPR polymorphism - 2/4  found an association 
Family based 5-HTTLPR polymorphism – one study found an association 
Another study found an association with combined type 
Third study found no association 
TPH Family based 2 studies did not find an association 
1 study - rs1843809 T-allele, rs1386497 A-allele, and rs1386493 
C-allele – association 
2nd study - rs1843809 A-allele and rs1386493 G-allele –
association 
SNAP25 Family based 
Meta-analysis 
Family based 
T1069C and T1065G – association, not replicated 
T1065G association with ADHD  
rs66039806-C, rs362549-A, rs362987-A, rs362998-C alleles, 
rs363020, rs362567- association, not all replicated 
BDNF Case control Val66 allele parental transmission and association of ADHD, not 
replicated 
No association with 20 SNPs 
Glutamate Family based GRIN2A , Association, not replicated 
Haplotype –weak association 
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